0002039072 2025-01-01 2025-12-31 0002039072 dei:BusinessContactMember 2025-01-01 2025-12-31 0002039072 2024-01-01 2024-12-31 0002039072 2025-12-31 0002039072 2024-12-31 0002039072 ifrs-full:IssuedCapitalMember 2023-12-31 0002039072 ifrs-full:SharePremiumMember 2023-12-31 0002039072 ifrs-full:RetainedEarningsMember 2023-12-31 0002039072 2023-12-31 0002039072 ifrs-full:IssuedCapitalMember 2024-12-31 0002039072 ifrs-full:SharePremiumMember 2024-12-31 0002039072 ifrs-full:RetainedEarningsMember 2024-12-31 0002039072 ifrs-full:IssuedCapitalMember 2024-01-01 2024-12-31 0002039072 ifrs-full:SharePremiumMember 2024-01-01 2024-12-31 0002039072 ifrs-full:RetainedEarningsMember 2024-01-01 2024-12-31 0002039072 ifrs-full:IssuedCapitalMember 2025-01-01 2025-12-31 0002039072 ifrs-full:SharePremiumMember 2025-01-01 2025-12-31 0002039072 ifrs-full:RetainedEarningsMember 2025-01-01 2025-12-31 0002039072 ifrs-full:IssuedCapitalMember 2025-12-31 0002039072 ifrs-full:SharePremiumMember 2025-12-31 0002039072 ifrs-full:RetainedEarningsMember 2025-12-31 0002039072 DAVI:BreastCheckIPRightsMember 2025-12-31 0002039072 DAVI:BreastCheckIPRightsMember 2024-12-31 0002039072 DAVI:TricosIPRightsMember 2025-12-31 0002039072 DAVI:TricosIPRightsMember 2024-12-31 0002039072 DAVI:TesticIPRightsMember 2025-12-31 0002039072 DAVI:TesticIPRightsMember 2024-12-31 0002039072 DAVI:DavionMasksIPRightsMember 2025-12-31 0002039072 DAVI:DavionMasksIPRightsMember 2024-12-31 0002039072 DAVI:BioGenexIPRightsMember 2025-12-31 0002039072 DAVI:BioGenexIPRightsMember 2024-12-31 0002039072 DAVI:MeritIPRightsMember 2025-12-31 0002039072 DAVI:MeritIPRightsMember 2024-12-31 0002039072 ifrs-full:BottomOfRangeMember 2025-12-31 0002039072 ifrs-full:TopOfRangeMember 2025-12-31 0002039072 DAVI:JackKayeMember 2025-12-31 0002039072 DAVI:JackKayeMember 2024-12-31 0002039072 DAVI:JackKayeMember 2024-06-30 0002039072 DAVI:LaterThanFiveYearMember 2024-01-01 2024-12-31 0002039072 DAVI:LaterThanFiveYearMember 2025-01-01 2025-12-31 0002039072 2022-11-29 0002039072 2023-01-01 2023-12-31 0002039072 2025-08-31 0002039072 DAVI:July2026Member 2025-01-01 2025-12-31 0002039072 DAVI:TwelveMonthlyBeginningJuly2026Member 2025-01-01 2025-12-31 0002039072 DAVI:January2027Member 2025-01-01 2025-12-31 0002039072 DAVI:NeuRXMember DAVI:NeuRXSharesMember 2025-12-31 0002039072 DAVI:NonadjustingEventsAfterReportingPeriodMember 2026-01-02 0002039072 DAVI:NonadjustingEventsAfterReportingPeriodMember 2026-01-01 2026-01-02 0002039072 DAVI:CEOMember DAVI:NonadjustingEventsAfterReportingPeriodMember 2026-01-02 0002039072 DAVI:NonadjustingEventsAfterReportingPeriodMember 2026-02-28 0002039072 DAVI:NonadjustingEventsAfterReportingPeriodMember 2026-02-01 2026-02-28 0002039072 DAVI:NonadjustingEventsAfterReportingPeriodMember 2026-03-10 0002039072 DAVI:NeuRXMember 2025-09-01 2025-09-30 0002039072 DAVI:MrKayeMember 2025-12-31 0002039072 DAVI:MrKayeMember 2024-12-31 0002039072 DAVI:MrKayeMember 2025-01-01 2025-12-31 0002039072 DAVI:MrKayeMember 2024-06-30 0002039072 DAVI:DavidPaulMember 2024-06-30 0002039072 DAVI:MrKayeMember 2024-06-29 2024-06-30 0002039072 DAVI:JackKayeMember 2025-01-01 2025-12-31 0002039072 DAVI:DavidPaulAlexanderMember 2025-01-01 2025-12-31 0002039072 DAVI:MrTtofisMember 2025-12-01 2025-12-31 0002039072 DAVI:DavidPaulAlexanderMember 2024-01-01 2024-12-31 0002039072 DAVI:JackKayeMember 2024-01-01 2024-12-31 0002039072 srt:ScenarioPreviouslyReportedMember 2023-12-31 0002039072 srt:RestatementAdjustmentMember 2023-12-31 0002039072 srt:ScenarioPreviouslyReportedMember 2024-12-31 0002039072 srt:RestatementAdjustmentMember 2024-12-31 0002039072 srt:ScenarioPreviouslyReportedMember 2025-12-31 0002039072 srt:RestatementAdjustmentMember 2025-12-31 0002039072 srt:ScenarioPreviouslyReportedMember 2023-01-01 2023-12-31 0002039072 srt:RestatementAdjustmentMember 2023-01-01 2023-12-31 0002039072 srt:ScenarioPreviouslyReportedMember 2024-01-01 2024-12-31 0002039072 srt:RestatementAdjustmentMember 2024-01-01 2024-12-31 0002039072 srt:ScenarioPreviouslyReportedMember 2025-01-01 2025-12-31 0002039072 srt:RestatementAdjustmentMember 2025-01-01 2025-12-31 iso4217:EUR shares iso4217:EUR shares pure iso4217:USD DAVI:Decimal iso4217:USD shares true 2024 FY Amended to Address SEC Comments 0002039072 POS AM L2

DAVION HEALTHCARE PLC Unit A West Cork Business & Technology Park Clonakilty, County Cork P85 FV48 353 2238 808 958 David E Price 3 Bethesda Metro Center Suite 700 Bethesda MD 20814 202 536 5191 Non-accelerated Filer true false

1128807

1617024

-0

8159

-1128807

-1625183

-1128807

-1625183

-0.05

-0.07

25000000

22909836

2184618

2489448

17033 8138

122507

1058

140598

8149

2325216

2497597

250000

9395382

-8316348

-7187541

1329034

2457841

907671 0

88511

39756

996182

39756

2325216

2497597

200000

2925719

-5562358

-2436639

-1625183

5982 5594018 5600000 44018 875645 919663

250000

9395382

-7187541

2457841

-1128807

250000

9395382

-8316348

1329034

-1128807

-1625183

304830

8895 7807 122507 -0 906301 890915

48755

436577

-323

-668

1370

1047

-668

679

1058

0 5600000 0 919663

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 36px">1</td> <td>Significant accounting policies </td></tr> </table> 1.1 Reporting period These consolidated financial statements cover the financial years ended December 31, 2025 and 2024, as restated. Following discussions with the Staff of the United States Securities and Exchange Commission during its review of the Company’s registration statement, Management reassessed the US reporting of, and has restated the accounting treatment applied to the February 2023 transfer of certain intellectual property. For the purposes of these consolidated financial statements, the intellectual property has been recognised at its predecessor carrying amount rather than any asset acquisition value previously recognised. This revision affects the carrying amount of intangible assets, share premium and deficit together with the associated amortisation expense recognised in the restated consolidated financial statement reporting periods presented. The revision represents a change in the accounting treatment applied to the historical transaction for reporting purposes and does not affect: <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0"><tr style="vertical-align: top"> <td style="width: 0.5in"></td><td style="width: 0.25in">·</td><td style="text-align: justify">the legal ownership of the intellectual property;</td></tr> <tr style="vertical-align: top"> <td></td><td>·</td><td style="text-align: justify">the validity of the underlying transaction documentation;</td></tr> <tr style="vertical-align: top"> <td></td><td>·</td><td style="text-align: justify">the commercial rights associated with the intellectual property;</td></tr> <tr style="vertical-align: top"> <td></td><td>·</td><td style="text-align: justify">the Group's licensing arrangements; or</td></tr> <tr style="vertical-align: top"> <td></td><td>·</td><td style="text-align: justify">the Directors' strategy for commercialising the Group's technologies.</td></tr></table> <p id="xdx_84B_eifrs-full--ExplanationOfMeasurementBasesForFinancialInstrumentsUsedInPreparingFinancialStatementsExplanatory_zE6VemVHeSpd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt">1.2 Accounting convention The consolidated financial statements have been prepared in accordance with International Financial Reporting Standards (“IFRS”) as issued by the International Accounting Standards Board (“IASB”). The consolidated financial statements are prepared in Euros, which is the functional currency of the Company. Monetary amounts in these consolidated financial statements are rounded to the nearest Euro, unless the context otherwise indicates. The consolidated financial statements have been prepared under the historical cost convention. The principal accounting policies adopted are set out below. The consolidated financial statements consist of the financial statements of the parent Company, Davion Healthcare Plc, together with its wholly owned subsidiary, Davion Healthcare Ltd (Cyprus). On January 1, 2026 the Company acquired 100% of Davion Healthcare Corporation. All the financial statements are made up to December 31, 2025 and 2024. Where necessary, adjustments are made to the financial statements of the subsidiary to bring the accounting policies used into line with those used by other subsidiaries of the Company. All intra-Company transactions, balances and unrealised gains on transactions between the Company and its subsidiary are eliminated on consolidation. Unrealized losses are also eliminated unless the transaction provides evidence of an impairment of the asset transferred. The consolidated financial statements included in this Registration Statement have been prepared in accordance with International Financial Reporting Standards ("IFRS") as issued by the International Accounting Standards Board and reflect the accounting policies adopted for the purposes of this Registration Statement. Following discussions with the staff of the U.S. Securities and Exchange Commission during the review of this Registration Statement, the Company restated the historical accounting treatment applied to the February 2023 transfer of intellectual property. Accordingly, for the purposes of the financial statements included in this Registration Statement, the intellectual property is recognised at its predecessor carrying amount and is amortised on a straight-line basis over a finite useful economic life of ten years commencing on 6 February 2023. The comparative financial information has been restated to reflect this accounting treatment. The revisions reflected in these financial statements relate solely to the accounting measurement and presentation of the February 2023 transaction for the purposes of this Registration Statement. The revisions do not affect the legal validity of the Company's ownership of the intellectual property, the validity of the shares issued in connection with that transaction, the Company's patent portfolio, its licensing arrangements, its product portfolio or its commercial strategy. As a consequence of the restated accounting treatment, certain comparative balances, including intangible assets, accumulated amortisation, retained earnings, shareholders' equity and related disclosures, have been restated from those previously reported. The accompanying notes to the consolidated financial statements describe the nature and effect of these revisions. 1.3 Liquidity The Company incurred a loss of €1,128,807 for the year ended December 31, 2025, and the Company’s current assets exceeded its current liabilities by €52,087. The Company has received a letter of support from its Chief Executive Officer stating that he will continue to support the Company for a period of 12 months from the approval of these consolidated financial statements. Management has concluded that based on all relevant factors, management does not believe that any material uncertainties exist that would cast significant doubt on Davion’s ability to continue as a going concern. See Note 3 Critical accounting policies and judgments for additional information on management’s evaluation. 1.4 Intangible assets other than goodwill Intellectual property rights acquired separately are initially measured at cost or, where applicable, at fair value depending on the nature of the underlying transaction and the form of consideration transferred. Intellectual property rights are considered to have finite useful economic lives and are amortised on a straight-line basis over their estimated useful economic life of 10 years from the date the asset is available for use. In respect of the intellectual property transferred in February 2023, amortisation commenced on 6 February 2023. The amortisation charge is recognised within profit or loss. The useful economic life, residual value and amortisation method are reviewed at each reporting date and adjusted prospectively where appropriate to reflect changes in expected patterns of consumption of the future economic benefits embodied in the asset. An intangible asset is derecognised on disposal or when no future economic benefits are expected from its use or disposal. Any gain or loss arising on derecognition is recognised in profit or loss and is measured as the difference between the net disposal proceeds and the carrying amount of the asset. At each reporting date, the Company assesses whether there is any indication that an intangible asset may be impaired. Where such an indication exists, the recoverable amount of the asset is estimated. The recoverable amount is the higher of its fair value less costs of disposal and its value in use. If the recoverable amount of an asset is estimated to be less than its carrying amount, the carrying amount is reduced to its recoverable amount and an impairment loss is recognised immediately in profit or loss. Where an impairment loss subsequently reverses, the carrying amount of the asset is increased to the revised estimate of its recoverable amount, provided that the increased carrying amount does not exceed the carrying amount that would have been determined had no impairment loss been recognised in prior periods. Any reversal of an impairment loss is recognised immediately in profit or loss. 1.5 Impairment of tangible and intangible assets At each reporting end date, the Company reviews the carrying amounts of its tangible assets to determine whether there is any indication that those assets have suffered an impairment loss. If any such indication exists, the recoverable amount of the asset is estimated in order to determine the extent of the impairment loss (if any). Where it is not possible to estimate the recoverable amount of an individual asset, the Company estimates the recoverable amount of the cash-generating unit to which the asset belongs. Intangible assets with indefinite useful lives and intangible assets not yet available for use are tested for impairment annually, and whenever there is an indication that the asset may be impaired. The Company’s recognised intellectual property at December 31, 2025 and 2024 has a finite useful life and is therefore not included within the category of indefinite-lived intangible assets referred to above. The recoverable amount is the higher of fair value less costs to sell and value in use. In assessing value in use, the estimated future cash flows are discounted to their present value using a pretax discount rate that reflects current market assessments of the time value of money and the risks specific to the asset for which the estimates of future cash flows have not been adjusted. If the recoverable amount of an asset (or cash-generating unit) is estimated to be less than its carrying amount, the carrying amount of the asset (or cash-generating unit) is reduced to its recoverable amount. An impairment loss is recognised immediately in profit or loss, unless the relevant asset is carried at a revalued amount, in which case the impairment loss is treated as a revaluation decrease. Where an impairment loss subsequently reverses, the carrying amount of the asset (or cash-generating unit) is increased to the revised estimate of its recoverable amount, but so that the increased carrying amount does not exceed the carrying amount that would have been determined had no impairment loss been recognised for the asset (or cash-generating unit) in prior years. A reversal of an impairment loss is recognised immediately in profit or loss, unless the relevant asset is carried at a revalued amount, in which case the reversal of the impairment loss is treated as a revaluation increase. 1.6 Cash and cash equivalents Cash and cash equivalents include cash on hand, deposits held at call with banks, other short-term liquid investments with original maturities of three months or less, and bank overdrafts. Bank overdrafts are shown within borrowings in current liabilities. Cash and cash equivalents are carried at amortised cost because (i) they are held for collection of contractual cash flows and those cash flows represent sole payments of principal and interest, and (ii) they are not designated at Fair Value through Profit and Loss. 1.7 Financial assets Financial assets are recognised in the Company’s consolidated statement of financial position when the Company becomes party to the contractual provisions of the instrument. Financial assets are classified into specified categories, depending on the nature and purpose of the financial assets. All purchases and sales of financial assets that require delivery within the time frame established by regulation or market convention (“regular way” purchases and sales) are recorded at trade date, which is the date when the Company commits to deliver a financial instrument. All other purchases and sales are recognised when the entity becomes a party to the contractual provisions of the instrument. Financial assets are derecognised when the rights to receive cash flows from the financial assets have expired or have been transferred and the Company has transferred substantially all the risks and rewards of ownership. Financial assets at fair value through profit or loss IFRS 13 establishes a single source of guidance for all fair value measurements. IFRS 13 does not change when an entity is required to use fair value, but rather provides guidance on how to measure fair value under IFRS when fair value is required or permitted. The resulting calculations under IFRS 13 affected the principles that the Company uses to assess the fair value, but the assessment of fair value under IFRS 13 has not materially changed the fair values recognised or disclosed. IFRS 13 mainly impacts the disclosures of the Company. It requires specific disclosures about fair value measurements and disclosures of fair values, some of which replace existing disclosure requirements in other standards. Financial assets held at amortised cost Financial instruments are classified as financial assets measured at amortised cost where the objective is to hold these assets in order to collect contractual cash flows, and the contractual cash flows are solely payments of principal and interest. They arise principally from the provision of goods and services to customers (e.g, trade receivables). They are initially recognised at fair value plus transaction costs directly attributable to their acquisition or issue, and are subsequently carried at amortised cost using the effective interest rate method, less provision for impairment where necessary. Impairment of financial assets Financial assets carried at amortised cost and Fair Value Through Other Comprehensive Income are assessed for indicators of impairment at each reporting end date. The expected credit losses associated with these assets are estimated on a forward-looking basis. A broad range of information is considered when assessing credit risk and measuring expected credit losses, including past events, current conditions, and reasonable and supportable forecasts that affect the expected collectability of the future cash flows of the instrument. For trade receivables, the simplified approach permitted by IFRS 9 is applied, which requires expected lifetime losses to be recognised from initial recognition of the receivables. Derecognition of financial assets Financial assets are derecognised only when the contractual rights to the cash flows from the asset expire, or when it transfers the financial asset and substantially all the risks and rewards of ownership to another entity. 1.8 Financial liabilities The Company recognizes financial debt when the Company becomes a party to the contractual provisions of the instruments. Financial liabilities are classified as either “financial liabilities at fair value through profit or loss” or “other financial liabilities.” Other financial liabilities Other financial liabilities, including borrowings, trade payables and other short-term monetary liabilities, are initially measured at fair value net of transaction costs directly attributable to the issuance of the financial liability. They are subsequently measured at amortised cost using the effective interest method. For the purposes of each financial liability, interest expense includes initial transaction costs and any premium payable on redemption, as well as any interest or coupon payable while the liability is outstanding. Derecognition of financial liabilities Financial liabilities are derecognised when, and only when, the Company’s obligations are discharged, cancelled, or they expire. 1.9 Equity instruments Equity instruments issued by the Company are recorded at the proceeds received or at the fair value of shares issued, net of direct issue costs, as appropriate. Dividends payable on equity instruments are recognised as liabilities once they are no longer at the discretion of the Company. 1.10 Taxation Income tax expense represents the sum of the tax currently payable and deferred tax. Current tax The tax currently payable is based on taxable profit for the year. Taxable profit differs from net profit as reported in the Consolidated Statements of Operations because it excludes items of income or expense that are taxable or deductible in other years and it further excludes items that are never taxable or deductible. The Company’s liability for current tax is calculated using tax rates that have been enacted or substantively enacted by the reporting end date. Deferred tax Deferred tax is the tax expected to be payable or recoverable on differences between the carrying amounts of assets and liabilities in the consolidated financial statements and the corresponding tax bases used in the computation of taxable profit, and is accounted for using the balance sheet liability method. Deferred tax liabilities are generally recognised for all taxable temporary differences, and deferred tax assets are recognised to the extent that it is probable that taxable profits will be available against which deductible temporary differences, can be utilised. Such assets and liabilities are not recognised if the temporary difference arises from goodwill or from the initial recognition of other assets and liabilities in a transaction that affects neither the tax profit nor the accounting profit. As of December 31, 2025, the Group had unutilised corporation tax assets of €931,583 (2024: €828,586) available for offset against future taxable profits. These losses arise in the Ireland and Cyprus tax jurisdiction and may be carried forward indefinitely under local tax legislation. In accordance with IAS 12 – Income Taxes, no deferred tax asset has been recognised in respect of these losses due to the uncertainty regarding the availability of sufficient future taxable profits against which the losses can be utilised. Management will continue to assess the recoverability of these tax losses and will recognise a deferred tax asset when it is considered probable that future taxable profits will be available. 1.11 Foreign exchange Transactions in currencies other than euros are recorded at the rates of exchange prevailing at the dates of the transactions. At each reporting end date, monetary assets and liabilities that are denominated in foreign currencies are remeasured at the rates prevailing on the reporting end date. Gains and losses arising on remeasurement in the period are included in profit or loss. 1.12 Research and development costs Research expenditures are written off against profits in the year in which it is incurred. Identifiable development expenditure is capitalised to the extent that the technical, commercial and financial feasibility can be demonstrated. 1.13 Segments The Company has been operating as a single segment for financial reporting purposes since its inception. The Chief Operating Decision Maker is the CEO who is responsible for making all decisions regarding the use of capital. Less than 1% of the Company’s total assets are located in Ireland. 1.14 Revenue The Company recognizes revenue in accordance with IFRS 15 Revenue from Contracts with Customers, which establishes a five-step model for recognizing revenue arising from contracts with customers. Revenue is recognized when control of promised goods or services is transferred to the customer in an amount that reflects the consideration to which the Company expects to be entitled. Where the Company generates revenue primarily from licensing arrangements that grant third parties rights to use the Company’s intellectual property (“IP”), which may include proprietary technology, know-how, trademarks, and related platform access. Licensing arrangements may include fixed license fees, minimum guaranteed payments, milestone payments, and sales- or usage-based royalties. The Company evaluates its contracts using the following steps: <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 3%"> </td> <td style="text-align: justify; width: 3%">1.</td> <td style="text-align: justify; width: 94%">Identification of the contract with a customer</td></tr> <tr style="vertical-align: top"> <td> </td> <td style="text-align: justify">2.</td> <td style="text-align: justify">Identification of performance obligations in the contract</td></tr> <tr style="vertical-align: top"> <td> </td> <td style="text-align: justify">3.</td> <td style="text-align: justify">Determination of the transaction price</td></tr> <tr style="vertical-align: top"> <td> </td> <td style="text-align: justify">4.</td> <td style="text-align: justify">Allocation of the transaction price to performance obligations</td></tr> <tr style="vertical-align: top"> <td> </td> <td style="text-align: justify">5.</td> <td style="text-align: justify">Recognition of revenue when or as performance obligations are satisfied.</td></tr> </table> Licensing of Intellectual Property The Company evaluates the nature of licenses granted to determine whether they represent a right to access intellectual property, or a right to use intellectual property as it exists at the point in time the license is granted. Licenses that provide a right to use intellectual property are typically satisfied at a point in time, generally when the license is made available to the licensee and the license period begins. Licenses that provide a right to access intellectual property, where the Company is expected to undertake activities that significantly affect the intellectual property during the license term, are satisfied over time during the license period. Fixed License Fees Certain licensing arrangements include fixed license fees or fixed minimum payments that are contractually payable regardless of the licensee’s future sales or usage. Where the license represents a right to use intellectual property, the fixed license fee is generally recognized at the point in time when the license is transferred to the licensee, provided that collectability of the consideration is probable. Where the license represents a right to access intellectual property, the fixed license fee is recognized over the license period, typically on a straight-line basis or another measure that reflects the pattern of transfer of control. Installment payments of fixed license fees are recognized as revenue when the underlying performance obligation is satisfied, and the Company records a contract asset or receivable when the right to payment becomes unconditional. Certain license agreements provide for minimum guaranteed payments, which may be structured as: minimum royalty payments; minimum annual license fees; or advance royalty payments. Minimum guaranteed amounts represent fixed consideration under the contract. These amounts are included in the transaction price at contract inception, subject to the Company’s assessment of collectability. When minimum guaranteed payments relate to a license that is satisfied at a point in time, the minimum guaranteed consideration is recognized when the license is made available to the licensee. When minimum guaranteed payments relate to a license that is satisfied over time, revenue is recognized over the period the license provides access to the intellectual property, unless another pattern better reflects the transfer of the licensed rights. Where minimum guaranteed payments represent advance royalties, such amounts are initially recorded as contract liabilities and recognized as revenue as the underlying performance obligations are satisfied. Royalties The Company’s licensing agreements may include sales-based or usage-based royalties payable by licensees based on the licensee’s sales of products incorporating the Company’s intellectual property or based on other usage metrics. In accordance with the sales- or usage-based royalty exception in IFRS 15, royalty revenue is recognized only when the subsequent sales or usage occur, which is the point at which the uncertainty associated with the variable consideration is resolved. Accordingly, royalty revenue is recognized in the period in which the licensee’s underlying sales or usage occurs, as reported by the licensee. To the extent that minimum guaranteed royalties exceed the royalties earned based on actual sales or usage, the guaranteed amount is recognized as revenue in accordance with the pattern of satisfaction of the underlying license performance obligation. If royalties earned based on actual sales exceed the minimum guaranteed amounts, the excess royalty revenue is recognized in the period in which the underlying sales occur. Contract Balances Contract assets represent the Company’s right to consideration in exchange for goods or services transferred to customers when that right is conditional on something other than the passage of time. Contract liabilities represent payments received in advance of the Company satisfying the related performance obligations, including advances of license fees or royalty payments. Contract liabilities are recognized as revenue when the Company satisfies the associated performance obligations. 1.15 Share-based payments The Company accounts for share-based payment transactions in accordance with IFRS 2 – Share-based Payment. Share-based payment transactions occur when the Company receives goods or services as consideration for equity instruments of the Company or for amounts based on the value of the Company’s equity instruments. The Company may grant equity instruments to employees, directors, consultants and other service providers as compensation for services rendered. Equity-settled share-based payments Equity-settled share-based payments are measured at the fair value of the equity instruments granted at the grant date. The fair value determined at the grant date is recognized as an expense, together with a corresponding increase in equity, over the vesting period, which represents the period during which the relevant services are rendered. At the end of each reporting period, the Company revises its estimates of the number of equity instruments expected to vest based on the assessment of vesting conditions. The impact of the revision of the original estimates, if any, is recognized in profit or loss such that the cumulative expense reflects the revised estimate. No expense is recognized for awards that do not ultimately vest because non-market vesting conditions have not been satisfied. Cash-settled share-based payments For cash-settled share-based payment transactions, the Company recognizes a liability for the goods or services acquired. The liability is measured initially and at each reporting date until settlement at the fair value of the liability, with changes in fair value recognized in profit or loss for the period. The liability is recognized over the vesting period, based on the Company’s estimate of the number of awards expected to vest. Transactions with non-employees Share-based payments issued to consultants, advisors and other non-employees in exchange for services are measured at the fair value of the goods or services received. If the fair value of the services received cannot be reliably measured, the transaction is measured by reference to the fair value of the equity instruments granted. The fair value of the equity instruments is measured at the date the entity obtains the goods or the counterparty renders the service. Vesting conditions Vesting conditions may include service conditions or performance conditions. Service conditions require the counterparty to complete a specified period of service. Performance conditions require specified performance targets to be achieved. Where awards vest upon the occurrence of a non-market performance condition, such as the completion of a financing transaction or a successful public listing, expense is recognized only when it becomes probable that the vesting condition will be satisfied. If the vesting condition is not satisfied, no expense is recognized. Market conditions Market conditions are performance conditions related to the market price of the Company’s equity instruments. Market conditions are reflected in the grant-date fair value of the equity instruments granted and are not subsequently adjusted for actual outcomes. Measurement of fair value The Company measures the fair value of share-based payment awards using appropriate valuation techniques. For option-based awards, the Company typically uses the Black-Scholes option pricing model or other appropriate valuation methodologies. The valuation models incorporate assumptions including: <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 0.25in"> </td> <td style="width: 0.25in; text-align: justify">·</td> <td style="text-align: justify">expected volatility</td></tr> <tr style="vertical-align: top"> <td> </td> <td style="text-align: justify">·</td> <td style="text-align: justify">risk-free interest rate</td></tr> <tr style="vertical-align: top"> <td> </td> <td style="text-align: justify">·</td> <td style="text-align: justify">expected term of the award</td></tr> <tr style="vertical-align: top"> <td> </td> <td style="text-align: justify">·</td> <td style="text-align: justify">expected dividends.</td></tr> </table> These assumptions are determined using management’s best estimates and observable market data where available. Share-based payments related to capital markets transactions The Company may issue equity instruments to advisors, consultants or other service providers in connection with capital raising or public listing transactions. Where equity instruments are issued in exchange for advisory or professional services, the transaction is accounted for as an equity-settled share-based payment. If the issuance of equity instruments is contingent upon the successful completion of a transaction, such as a public listing, the Company recognizes expense only when the performance condition has been satisfied. The share-based payment expense is measured at the fair value of the equity instruments issued at the date the condition is satisfied. Presentation in the consolidated financial statements Share-based payment expenses are recognized in profit or loss within operating expenses, unless the services received qualify for capitalization as part of the cost of an asset under another IFRS standard. The corresponding credit is recognized within equity, typically within share premium or additional paid-in capital. Modification, cancellation and settlement of awards If the terms of an equity-settled share-based payment arrangement are modified, the Company recognizes, at a minimum, the expense based on the grant-date fair value of the original award. Any incremental fair value granted is recognized over the remaining vesting period. If an award is cancelled or settled during the vesting period, the Company recognizes immediately the amount that would otherwise have been recognized over the remainder of the vesting period. 1.16 Cloud computing arrangements The Company enters into cloud computing arrangements for infrastructure and application hosting. The Company evaluates these arrangements to determine whether they contain a lease under IFRS 16. If the arrangement does not convey the right to control the use of an identified asset, the arrangement is accounted for as a service contract. Fees paid for cloud infrastructure and software-as-a-service (“SaaS”) solutions are recognized as operating expenses as the services are received. Costs incurred to configure or customize cloud computing arrangements are expensed as incurred unless those costs result in the creation of a separately identifiable intangible asset controlled by the Company. Payments made in advance of the related service period are recognized as prepaid assets and amortized over the service period. 1.17 Fair Value For financial reporting purposes, fair value measurements are categorized into Level 1, 2 or 3 based on the degree to which inputs to the fair value measurements are observable and the significance of the inputs to the fair value measurement in its entirety, which are described as follows: Level 1: quoted prices (unadjusted) in active markets for identical assets or liabilities. Level 2: valuation techniques for which the lowest level of inputs which have a significant effect on the recorded fair value are observable, either directly or indirectly. Level 3: valuation techniques for which the lowest level of inputs that have a significant effect on the recorded fair value are not based on observable market data.

1.1 Reporting period These consolidated financial statements cover the financial years ended December 31, 2025 and 2024, as restated. Following discussions with the Staff of the United States Securities and Exchange Commission during its review of the Company’s registration statement, Management reassessed the US reporting of, and has restated the accounting treatment applied to the February 2023 transfer of certain intellectual property. For the purposes of these consolidated financial statements, the intellectual property has been recognised at its predecessor carrying amount rather than any asset acquisition value previously recognised. This revision affects the carrying amount of intangible assets, share premium and deficit together with the associated amortisation expense recognised in the restated consolidated financial statement reporting periods presented. The revision represents a change in the accounting treatment applied to the historical transaction for reporting purposes and does not affect: <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0"><tr style="vertical-align: top"> <td style="width: 0.5in"></td><td style="width: 0.25in">·</td><td style="text-align: justify">the legal ownership of the intellectual property;</td></tr> <tr style="vertical-align: top"> <td></td><td>·</td><td style="text-align: justify">the validity of the underlying transaction documentation;</td></tr> <tr style="vertical-align: top"> <td></td><td>·</td><td style="text-align: justify">the commercial rights associated with the intellectual property;</td></tr> <tr style="vertical-align: top"> <td></td><td>·</td><td style="text-align: justify">the Group's licensing arrangements; or</td></tr> <tr style="vertical-align: top"> <td></td><td>·</td><td style="text-align: justify">the Directors' strategy for commercialising the Group's technologies.</td></tr></table>

<p id="xdx_84B_eifrs-full--ExplanationOfMeasurementBasesForFinancialInstrumentsUsedInPreparingFinancialStatementsExplanatory_zE6VemVHeSpd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt">1.2 Accounting convention The consolidated financial statements have been prepared in accordance with International Financial Reporting Standards (“IFRS”) as issued by the International Accounting Standards Board (“IASB”). The consolidated financial statements are prepared in Euros, which is the functional currency of the Company. Monetary amounts in these consolidated financial statements are rounded to the nearest Euro, unless the context otherwise indicates. The consolidated financial statements have been prepared under the historical cost convention. The principal accounting policies adopted are set out below. The consolidated financial statements consist of the financial statements of the parent Company, Davion Healthcare Plc, together with its wholly owned subsidiary, Davion Healthcare Ltd (Cyprus). On January 1, 2026 the Company acquired 100% of Davion Healthcare Corporation. All the financial statements are made up to December 31, 2025 and 2024. Where necessary, adjustments are made to the financial statements of the subsidiary to bring the accounting policies used into line with those used by other subsidiaries of the Company. All intra-Company transactions, balances and unrealised gains on transactions between the Company and its subsidiary are eliminated on consolidation. Unrealized losses are also eliminated unless the transaction provides evidence of an impairment of the asset transferred. The consolidated financial statements included in this Registration Statement have been prepared in accordance with International Financial Reporting Standards ("IFRS") as issued by the International Accounting Standards Board and reflect the accounting policies adopted for the purposes of this Registration Statement. Following discussions with the staff of the U.S. Securities and Exchange Commission during the review of this Registration Statement, the Company restated the historical accounting treatment applied to the February 2023 transfer of intellectual property. Accordingly, for the purposes of the financial statements included in this Registration Statement, the intellectual property is recognised at its predecessor carrying amount and is amortised on a straight-line basis over a finite useful economic life of ten years commencing on 6 February 2023. The comparative financial information has been restated to reflect this accounting treatment. The revisions reflected in these financial statements relate solely to the accounting measurement and presentation of the February 2023 transaction for the purposes of this Registration Statement. The revisions do not affect the legal validity of the Company's ownership of the intellectual property, the validity of the shares issued in connection with that transaction, the Company's patent portfolio, its licensing arrangements, its product portfolio or its commercial strategy. As a consequence of the restated accounting treatment, certain comparative balances, including intangible assets, accumulated amortisation, retained earnings, shareholders' equity and related disclosures, have been restated from those previously reported. The accompanying notes to the consolidated financial statements describe the nature and effect of these revisions.

1.3 Liquidity The Company incurred a loss of €1,128,807 for the year ended December 31, 2025, and the Company’s current assets exceeded its current liabilities by €52,087. The Company has received a letter of support from its Chief Executive Officer stating that he will continue to support the Company for a period of 12 months from the approval of these consolidated financial statements. Management has concluded that based on all relevant factors, management does not believe that any material uncertainties exist that would cast significant doubt on Davion’s ability to continue as a going concern. See Note 3 Critical accounting policies and judgments for additional information on management’s evaluation.

-1128807

52087

1.4 Intangible assets other than goodwill Intellectual property rights acquired separately are initially measured at cost or, where applicable, at fair value depending on the nature of the underlying transaction and the form of consideration transferred. Intellectual property rights are considered to have finite useful economic lives and are amortised on a straight-line basis over their estimated useful economic life of 10 years from the date the asset is available for use. In respect of the intellectual property transferred in February 2023, amortisation commenced on 6 February 2023. The amortisation charge is recognised within profit or loss. The useful economic life, residual value and amortisation method are reviewed at each reporting date and adjusted prospectively where appropriate to reflect changes in expected patterns of consumption of the future economic benefits embodied in the asset. An intangible asset is derecognised on disposal or when no future economic benefits are expected from its use or disposal. Any gain or loss arising on derecognition is recognised in profit or loss and is measured as the difference between the net disposal proceeds and the carrying amount of the asset. At each reporting date, the Company assesses whether there is any indication that an intangible asset may be impaired. Where such an indication exists, the recoverable amount of the asset is estimated. The recoverable amount is the higher of its fair value less costs of disposal and its value in use. If the recoverable amount of an asset is estimated to be less than its carrying amount, the carrying amount is reduced to its recoverable amount and an impairment loss is recognised immediately in profit or loss. Where an impairment loss subsequently reverses, the carrying amount of the asset is increased to the revised estimate of its recoverable amount, provided that the increased carrying amount does not exceed the carrying amount that would have been determined had no impairment loss been recognised in prior periods. Any reversal of an impairment loss is recognised immediately in profit or loss.

1.5 Impairment of tangible and intangible assets At each reporting end date, the Company reviews the carrying amounts of its tangible assets to determine whether there is any indication that those assets have suffered an impairment loss. If any such indication exists, the recoverable amount of the asset is estimated in order to determine the extent of the impairment loss (if any). Where it is not possible to estimate the recoverable amount of an individual asset, the Company estimates the recoverable amount of the cash-generating unit to which the asset belongs. Intangible assets with indefinite useful lives and intangible assets not yet available for use are tested for impairment annually, and whenever there is an indication that the asset may be impaired. The Company’s recognised intellectual property at December 31, 2025 and 2024 has a finite useful life and is therefore not included within the category of indefinite-lived intangible assets referred to above. The recoverable amount is the higher of fair value less costs to sell and value in use. In assessing value in use, the estimated future cash flows are discounted to their present value using a pretax discount rate that reflects current market assessments of the time value of money and the risks specific to the asset for which the estimates of future cash flows have not been adjusted. If the recoverable amount of an asset (or cash-generating unit) is estimated to be less than its carrying amount, the carrying amount of the asset (or cash-generating unit) is reduced to its recoverable amount. An impairment loss is recognised immediately in profit or loss, unless the relevant asset is carried at a revalued amount, in which case the impairment loss is treated as a revaluation decrease. Where an impairment loss subsequently reverses, the carrying amount of the asset (or cash-generating unit) is increased to the revised estimate of its recoverable amount, but so that the increased carrying amount does not exceed the carrying amount that would have been determined had no impairment loss been recognised for the asset (or cash-generating unit) in prior years. A reversal of an impairment loss is recognised immediately in profit or loss, unless the relevant asset is carried at a revalued amount, in which case the reversal of the impairment loss is treated as a revaluation increase.

1.6 Cash and cash equivalents Cash and cash equivalents include cash on hand, deposits held at call with banks, other short-term liquid investments with original maturities of three months or less, and bank overdrafts. Bank overdrafts are shown within borrowings in current liabilities. Cash and cash equivalents are carried at amortised cost because (i) they are held for collection of contractual cash flows and those cash flows represent sole payments of principal and interest, and (ii) they are not designated at Fair Value through Profit and Loss.

1.7 Financial assets Financial assets are recognised in the Company’s consolidated statement of financial position when the Company becomes party to the contractual provisions of the instrument. Financial assets are classified into specified categories, depending on the nature and purpose of the financial assets. All purchases and sales of financial assets that require delivery within the time frame established by regulation or market convention (“regular way” purchases and sales) are recorded at trade date, which is the date when the Company commits to deliver a financial instrument. All other purchases and sales are recognised when the entity becomes a party to the contractual provisions of the instrument. Financial assets are derecognised when the rights to receive cash flows from the financial assets have expired or have been transferred and the Company has transferred substantially all the risks and rewards of ownership. Financial assets at fair value through profit or loss IFRS 13 establishes a single source of guidance for all fair value measurements. IFRS 13 does not change when an entity is required to use fair value, but rather provides guidance on how to measure fair value under IFRS when fair value is required or permitted. The resulting calculations under IFRS 13 affected the principles that the Company uses to assess the fair value, but the assessment of fair value under IFRS 13 has not materially changed the fair values recognised or disclosed. IFRS 13 mainly impacts the disclosures of the Company. It requires specific disclosures about fair value measurements and disclosures of fair values, some of which replace existing disclosure requirements in other standards. Financial assets held at amortised cost Financial instruments are classified as financial assets measured at amortised cost where the objective is to hold these assets in order to collect contractual cash flows, and the contractual cash flows are solely payments of principal and interest. They arise principally from the provision of goods and services to customers (e.g, trade receivables). They are initially recognised at fair value plus transaction costs directly attributable to their acquisition or issue, and are subsequently carried at amortised cost using the effective interest rate method, less provision for impairment where necessary. Impairment of financial assets Financial assets carried at amortised cost and Fair Value Through Other Comprehensive Income are assessed for indicators of impairment at each reporting end date. The expected credit losses associated with these assets are estimated on a forward-looking basis. A broad range of information is considered when assessing credit risk and measuring expected credit losses, including past events, current conditions, and reasonable and supportable forecasts that affect the expected collectability of the future cash flows of the instrument. For trade receivables, the simplified approach permitted by IFRS 9 is applied, which requires expected lifetime losses to be recognised from initial recognition of the receivables. Derecognition of financial assets Financial assets are derecognised only when the contractual rights to the cash flows from the asset expire, or when it transfers the financial asset and substantially all the risks and rewards of ownership to another entity.

1.8 Financial liabilities The Company recognizes financial debt when the Company becomes a party to the contractual provisions of the instruments. Financial liabilities are classified as either “financial liabilities at fair value through profit or loss” or “other financial liabilities.” Other financial liabilities Other financial liabilities, including borrowings, trade payables and other short-term monetary liabilities, are initially measured at fair value net of transaction costs directly attributable to the issuance of the financial liability. They are subsequently measured at amortised cost using the effective interest method. For the purposes of each financial liability, interest expense includes initial transaction costs and any premium payable on redemption, as well as any interest or coupon payable while the liability is outstanding. Derecognition of financial liabilities Financial liabilities are derecognised when, and only when, the Company’s obligations are discharged, cancelled, or they expire.

1.9 Equity instruments Equity instruments issued by the Company are recorded at the proceeds received or at the fair value of shares issued, net of direct issue costs, as appropriate. Dividends payable on equity instruments are recognised as liabilities once they are no longer at the discretion of the Company.

1.10 Taxation Income tax expense represents the sum of the tax currently payable and deferred tax. Current tax The tax currently payable is based on taxable profit for the year. Taxable profit differs from net profit as reported in the Consolidated Statements of Operations because it excludes items of income or expense that are taxable or deductible in other years and it further excludes items that are never taxable or deductible. The Company’s liability for current tax is calculated using tax rates that have been enacted or substantively enacted by the reporting end date. Deferred tax Deferred tax is the tax expected to be payable or recoverable on differences between the carrying amounts of assets and liabilities in the consolidated financial statements and the corresponding tax bases used in the computation of taxable profit, and is accounted for using the balance sheet liability method. Deferred tax liabilities are generally recognised for all taxable temporary differences, and deferred tax assets are recognised to the extent that it is probable that taxable profits will be available against which deductible temporary differences, can be utilised. Such assets and liabilities are not recognised if the temporary difference arises from goodwill or from the initial recognition of other assets and liabilities in a transaction that affects neither the tax profit nor the accounting profit. As of December 31, 2025, the Group had unutilised corporation tax assets of €931,583 (2024: €828,586) available for offset against future taxable profits. These losses arise in the Ireland and Cyprus tax jurisdiction and may be carried forward indefinitely under local tax legislation. In accordance with IAS 12 – Income Taxes, no deferred tax asset has been recognised in respect of these losses due to the uncertainty regarding the availability of sufficient future taxable profits against which the losses can be utilised. Management will continue to assess the recoverability of these tax losses and will recognise a deferred tax asset when it is considered probable that future taxable profits will be available.

931583

828586

1.11 Foreign exchange Transactions in currencies other than euros are recorded at the rates of exchange prevailing at the dates of the transactions. At each reporting end date, monetary assets and liabilities that are denominated in foreign currencies are remeasured at the rates prevailing on the reporting end date. Gains and losses arising on remeasurement in the period are included in profit or loss.

1.12 Research and development costs Research expenditures are written off against profits in the year in which it is incurred. Identifiable development expenditure is capitalised to the extent that the technical, commercial and financial feasibility can be demonstrated.

1.13 Segments The Company has been operating as a single segment for financial reporting purposes since its inception. The Chief Operating Decision Maker is the CEO who is responsible for making all decisions regarding the use of capital. Less than 1% of the Company’s total assets are located in Ireland.

The Company has been operating as a single segment for financial reporting purposes since its inception. The Chief Operating Decision Maker is the CEO who is responsible for making all decisions regarding the use of capital. Less than 1% of the Company’s total assets are located in Ireland.

1.14 Revenue The Company recognizes revenue in accordance with IFRS 15 Revenue from Contracts with Customers, which establishes a five-step model for recognizing revenue arising from contracts with customers. Revenue is recognized when control of promised goods or services is transferred to the customer in an amount that reflects the consideration to which the Company expects to be entitled. Where the Company generates revenue primarily from licensing arrangements that grant third parties rights to use the Company’s intellectual property (“IP”), which may include proprietary technology, know-how, trademarks, and related platform access. Licensing arrangements may include fixed license fees, minimum guaranteed payments, milestone payments, and sales- or usage-based royalties. The Company evaluates its contracts using the following steps: <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 3%"> </td> <td style="text-align: justify; width: 3%">1.</td> <td style="text-align: justify; width: 94%">Identification of the contract with a customer</td></tr> <tr style="vertical-align: top"> <td> </td> <td style="text-align: justify">2.</td> <td style="text-align: justify">Identification of performance obligations in the contract</td></tr> <tr style="vertical-align: top"> <td> </td> <td style="text-align: justify">3.</td> <td style="text-align: justify">Determination of the transaction price</td></tr> <tr style="vertical-align: top"> <td> </td> <td style="text-align: justify">4.</td> <td style="text-align: justify">Allocation of the transaction price to performance obligations</td></tr> <tr style="vertical-align: top"> <td> </td> <td style="text-align: justify">5.</td> <td style="text-align: justify">Recognition of revenue when or as performance obligations are satisfied.</td></tr> </table> Licensing of Intellectual Property The Company evaluates the nature of licenses granted to determine whether they represent a right to access intellectual property, or a right to use intellectual property as it exists at the point in time the license is granted. Licenses that provide a right to use intellectual property are typically satisfied at a point in time, generally when the license is made available to the licensee and the license period begins. Licenses that provide a right to access intellectual property, where the Company is expected to undertake activities that significantly affect the intellectual property during the license term, are satisfied over time during the license period. Fixed License Fees Certain licensing arrangements include fixed license fees or fixed minimum payments that are contractually payable regardless of the licensee’s future sales or usage. Where the license represents a right to use intellectual property, the fixed license fee is generally recognized at the point in time when the license is transferred to the licensee, provided that collectability of the consideration is probable. Where the license represents a right to access intellectual property, the fixed license fee is recognized over the license period, typically on a straight-line basis or another measure that reflects the pattern of transfer of control. Installment payments of fixed license fees are recognized as revenue when the underlying performance obligation is satisfied, and the Company records a contract asset or receivable when the right to payment becomes unconditional. Certain license agreements provide for minimum guaranteed payments, which may be structured as: minimum royalty payments; minimum annual license fees; or advance royalty payments. Minimum guaranteed amounts represent fixed consideration under the contract. These amounts are included in the transaction price at contract inception, subject to the Company’s assessment of collectability. When minimum guaranteed payments relate to a license that is satisfied at a point in time, the minimum guaranteed consideration is recognized when the license is made available to the licensee. When minimum guaranteed payments relate to a license that is satisfied over time, revenue is recognized over the period the license provides access to the intellectual property, unless another pattern better reflects the transfer of the licensed rights. Where minimum guaranteed payments represent advance royalties, such amounts are initially recorded as contract liabilities and recognized as revenue as the underlying performance obligations are satisfied. Royalties The Company’s licensing agreements may include sales-based or usage-based royalties payable by licensees based on the licensee’s sales of products incorporating the Company’s intellectual property or based on other usage metrics. In accordance with the sales- or usage-based royalty exception in IFRS 15, royalty revenue is recognized only when the subsequent sales or usage occur, which is the point at which the uncertainty associated with the variable consideration is resolved. Accordingly, royalty revenue is recognized in the period in which the licensee’s underlying sales or usage occurs, as reported by the licensee. To the extent that minimum guaranteed royalties exceed the royalties earned based on actual sales or usage, the guaranteed amount is recognized as revenue in accordance with the pattern of satisfaction of the underlying license performance obligation. If royalties earned based on actual sales exceed the minimum guaranteed amounts, the excess royalty revenue is recognized in the period in which the underlying sales occur. Contract Balances Contract assets represent the Company’s right to consideration in exchange for goods or services transferred to customers when that right is conditional on something other than the passage of time. Contract liabilities represent payments received in advance of the Company satisfying the related performance obligations, including advances of license fees or royalty payments. Contract liabilities are recognized as revenue when the Company satisfies the associated performance obligations.

1.15 Share-based payments The Company accounts for share-based payment transactions in accordance with IFRS 2 – Share-based Payment. Share-based payment transactions occur when the Company receives goods or services as consideration for equity instruments of the Company or for amounts based on the value of the Company’s equity instruments. The Company may grant equity instruments to employees, directors, consultants and other service providers as compensation for services rendered. Equity-settled share-based payments Equity-settled share-based payments are measured at the fair value of the equity instruments granted at the grant date. The fair value determined at the grant date is recognized as an expense, together with a corresponding increase in equity, over the vesting period, which represents the period during which the relevant services are rendered. At the end of each reporting period, the Company revises its estimates of the number of equity instruments expected to vest based on the assessment of vesting conditions. The impact of the revision of the original estimates, if any, is recognized in profit or loss such that the cumulative expense reflects the revised estimate. No expense is recognized for awards that do not ultimately vest because non-market vesting conditions have not been satisfied. Cash-settled share-based payments For cash-settled share-based payment transactions, the Company recognizes a liability for the goods or services acquired. The liability is measured initially and at each reporting date until settlement at the fair value of the liability, with changes in fair value recognized in profit or loss for the period. The liability is recognized over the vesting period, based on the Company’s estimate of the number of awards expected to vest. Transactions with non-employees Share-based payments issued to consultants, advisors and other non-employees in exchange for services are measured at the fair value of the goods or services received. If the fair value of the services received cannot be reliably measured, the transaction is measured by reference to the fair value of the equity instruments granted. The fair value of the equity instruments is measured at the date the entity obtains the goods or the counterparty renders the service. Vesting conditions Vesting conditions may include service conditions or performance conditions. Service conditions require the counterparty to complete a specified period of service. Performance conditions require specified performance targets to be achieved. Where awards vest upon the occurrence of a non-market performance condition, such as the completion of a financing transaction or a successful public listing, expense is recognized only when it becomes probable that the vesting condition will be satisfied. If the vesting condition is not satisfied, no expense is recognized. Market conditions Market conditions are performance conditions related to the market price of the Company’s equity instruments. Market conditions are reflected in the grant-date fair value of the equity instruments granted and are not subsequently adjusted for actual outcomes. Measurement of fair value The Company measures the fair value of share-based payment awards using appropriate valuation techniques. For option-based awards, the Company typically uses the Black-Scholes option pricing model or other appropriate valuation methodologies. The valuation models incorporate assumptions including: <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 0.25in"> </td> <td style="width: 0.25in; text-align: justify">·</td> <td style="text-align: justify">expected volatility</td></tr> <tr style="vertical-align: top"> <td> </td> <td style="text-align: justify">·</td> <td style="text-align: justify">risk-free interest rate</td></tr> <tr style="vertical-align: top"> <td> </td> <td style="text-align: justify">·</td> <td style="text-align: justify">expected term of the award</td></tr> <tr style="vertical-align: top"> <td> </td> <td style="text-align: justify">·</td> <td style="text-align: justify">expected dividends.</td></tr> </table> These assumptions are determined using management’s best estimates and observable market data where available. Share-based payments related to capital markets transactions The Company may issue equity instruments to advisors, consultants or other service providers in connection with capital raising or public listing transactions. Where equity instruments are issued in exchange for advisory or professional services, the transaction is accounted for as an equity-settled share-based payment. If the issuance of equity instruments is contingent upon the successful completion of a transaction, such as a public listing, the Company recognizes expense only when the performance condition has been satisfied. The share-based payment expense is measured at the fair value of the equity instruments issued at the date the condition is satisfied. Presentation in the consolidated financial statements Share-based payment expenses are recognized in profit or loss within operating expenses, unless the services received qualify for capitalization as part of the cost of an asset under another IFRS standard. The corresponding credit is recognized within equity, typically within share premium or additional paid-in capital. Modification, cancellation and settlement of awards If the terms of an equity-settled share-based payment arrangement are modified, the Company recognizes, at a minimum, the expense based on the grant-date fair value of the original award. Any incremental fair value granted is recognized over the remaining vesting period. If an award is cancelled or settled during the vesting period, the Company recognizes immediately the amount that would otherwise have been recognized over the remainder of the vesting period.

1.16 Cloud computing arrangements The Company enters into cloud computing arrangements for infrastructure and application hosting. The Company evaluates these arrangements to determine whether they contain a lease under IFRS 16. If the arrangement does not convey the right to control the use of an identified asset, the arrangement is accounted for as a service contract. Fees paid for cloud infrastructure and software-as-a-service (“SaaS”) solutions are recognized as operating expenses as the services are received. Costs incurred to configure or customize cloud computing arrangements are expensed as incurred unless those costs result in the creation of a separately identifiable intangible asset controlled by the Company. Payments made in advance of the related service period are recognized as prepaid assets and amortized over the service period.

1.17 Fair Value For financial reporting purposes, fair value measurements are categorized into Level 1, 2 or 3 based on the degree to which inputs to the fair value measurements are observable and the significance of the inputs to the fair value measurement in its entirety, which are described as follows: Level 1: quoted prices (unadjusted) in active markets for identical assets or liabilities. Level 2: valuation techniques for which the lowest level of inputs which have a significant effect on the recorded fair value are observable, either directly or indirectly. Level 3: valuation techniques for which the lowest level of inputs that have a significant effect on the recorded fair value are not based on observable market data.

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 36px">2</td> <td>Adoption of new and revised IFRS accounting standards, new accounting policies and changes in accounting policies</td></tr> </table> Adoption of new and revised IFRS accounting standards The Company qualifies as an emerging growth company under the JOBS Act. However, because the Company prepares its consolidated financial statements in accordance with IFRS Accounting Standards as issued by the International Accounting Standards Board, the Company adopts new and amended IFRS Accounting Standards when they become effective under IFRS. Standards and amendments effective in the current year The following amendments are effective for annual periods beginning on or after January 1, 2025, and have been adopted by the Company: Lack of Exchangeability (Amendments to IAS 21). These amendments provide guidance for assessing whether a currency is exchangeable into another currency and, when it is not, for determining the exchange rate to be used and related disclosures. The adoption of these amendments did not have a material impact on the Company’s consolidated financial statements. The Company also considered the continuing application of recently effective amendments, including Classification of Liabilities as Current or Non-current and Non-current Liabilities with Covenants (Amendments to IAS 1), Lease Liability in a Sale and Leaseback (Amendments to IFRS 16), Supplier Finance Arrangements (Amendments to IAS 7 and IFRS 7), and International Tax Reform—Pillar Two Model Rules (Amendments to IAS 12). These amendments did not have a material impact on the Company’s consolidated financial statements. With respect to Pillar Two, the Company has applied the temporary mandatory exception to recognizing and disclosing deferred tax assets and liabilities related to Pillar Two income taxes. Based on the Company’s current facts and circumstances, management does not expect Pillar Two to have a material impact on the consolidated financial statements. Standards and amendments issued but not yet effective The following standards and amendments have been issued but are not yet effective and have not been early adopted by the Company: Amendments to the Classification and Measurement of Financial Instruments (Amendments to IFRS 9 and IFRS 7) and Annual Improvements to IFRS Accounting Standards—Volume 11. These amendments are effective for annual periods beginning on or after January 1, 2026. The Company is assessing the effect of these amendments on its consolidated financial statements. Based on its preliminary assessment, the Company does not currently expect a significant impact. IFRS 18, Presentation and Disclosure in Financial Statements is effective for annual periods beginning on or after January 1, 2027. The Company is evaluating the impact of IFRS 18 on the presentation and disclosure of its consolidated financial statements. New accounting policies adopted During 2025, the Company entered into certain arrangements involving the issuance of equity instruments to service providers in connection with corporate advisory and capital markets services related to the Company’s proposed NASDAQ direct listing. As a result, the Company adopted an accounting policy for share-based payments in accordance with IFRS 2 – Share-based Payment. As of December 31, 2025, certain equity compensation arrangements related to the advisory services were contingent upon the successful completion of the Company’s proposed listing on Nasdaq and therefore no share-based payment expense has been recognized in the accompanying consolidated financial statements. See Note 1.15 Share-based payments for a description of our accounting policy. In 2025, the Company entered into an intellectual property licensing arrangement with NeuRX Health Inc. (“NeuRX”) providing for future license and royalty revenues. As a result, the Company adopted an accounting policy for revenue recognition in accordance with IFRS – Revenue from Contracts with Customers. See Note 1.14 Revenue recognition for a description of our accounting policy and Note 17 Revenue for information on the licensing arrangement. Changes in accounting policies Except for the adoption of the policies described above, and as noted in note 1.1 and note 22, the accounting policies applied in the preparation of these consolidated financial statements are consistent with those applied in the Company’s consolidated financial statements for the year ended December 31, 2024.

Adoption of new and revised IFRS accounting standards The Company qualifies as an emerging growth company under the JOBS Act. However, because the Company prepares its consolidated financial statements in accordance with IFRS Accounting Standards as issued by the International Accounting Standards Board, the Company adopts new and amended IFRS Accounting Standards when they become effective under IFRS. Standards and amendments effective in the current year The following amendments are effective for annual periods beginning on or after January 1, 2025, and have been adopted by the Company: Lack of Exchangeability (Amendments to IAS 21). These amendments provide guidance for assessing whether a currency is exchangeable into another currency and, when it is not, for determining the exchange rate to be used and related disclosures. The adoption of these amendments did not have a material impact on the Company’s consolidated financial statements. The Company also considered the continuing application of recently effective amendments, including Classification of Liabilities as Current or Non-current and Non-current Liabilities with Covenants (Amendments to IAS 1), Lease Liability in a Sale and Leaseback (Amendments to IFRS 16), Supplier Finance Arrangements (Amendments to IAS 7 and IFRS 7), and International Tax Reform—Pillar Two Model Rules (Amendments to IAS 12). These amendments did not have a material impact on the Company’s consolidated financial statements. With respect to Pillar Two, the Company has applied the temporary mandatory exception to recognizing and disclosing deferred tax assets and liabilities related to Pillar Two income taxes. Based on the Company’s current facts and circumstances, management does not expect Pillar Two to have a material impact on the consolidated financial statements. Standards and amendments issued but not yet effective The following standards and amendments have been issued but are not yet effective and have not been early adopted by the Company: Amendments to the Classification and Measurement of Financial Instruments (Amendments to IFRS 9 and IFRS 7) and Annual Improvements to IFRS Accounting Standards—Volume 11. These amendments are effective for annual periods beginning on or after January 1, 2026. The Company is assessing the effect of these amendments on its consolidated financial statements. Based on its preliminary assessment, the Company does not currently expect a significant impact. IFRS 18, Presentation and Disclosure in Financial Statements is effective for annual periods beginning on or after January 1, 2027. The Company is evaluating the impact of IFRS 18 on the presentation and disclosure of its consolidated financial statements. New accounting policies adopted During 2025, the Company entered into certain arrangements involving the issuance of equity instruments to service providers in connection with corporate advisory and capital markets services related to the Company’s proposed NASDAQ direct listing. As a result, the Company adopted an accounting policy for share-based payments in accordance with IFRS 2 – Share-based Payment. As of December 31, 2025, certain equity compensation arrangements related to the advisory services were contingent upon the successful completion of the Company’s proposed listing on Nasdaq and therefore no share-based payment expense has been recognized in the accompanying consolidated financial statements. See Note 1.15 Share-based payments for a description of our accounting policy. In 2025, the Company entered into an intellectual property licensing arrangement with NeuRX Health Inc. (“NeuRX”) providing for future license and royalty revenues. As a result, the Company adopted an accounting policy for revenue recognition in accordance with IFRS – Revenue from Contracts with Customers. See Note 1.14 Revenue recognition for a description of our accounting policy and Note 17 Revenue for information on the licensing arrangement. Changes in accounting policies Except for the adoption of the policies described above, and as noted in note 1.1 and note 22, the accounting policies applied in the preparation of these consolidated financial statements are consistent with those applied in the Company’s consolidated financial statements for the year ended December 31, 2024.

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 36px">3</td> <td>Critical accounting estimates and judgements</td></tr> </table> In the application of the Company’s accounting policies, the directors are required to make judgements, estimates and assumptions about the carrying amount of assets and liabilities that are not readily apparent from other sources. In addition, management has exercised judgment in establishing accounting policies related to revenue recognition under the Company’s global licensing arrangement. As no revenue has been recognized to date, this judgment has not had a significant effect on the amounts recognized in the consolidated financial statements as of the reporting date. The estimates and associated assumptions are based on historical experience and other factors that are considered to be relevant. Actual results may differ from these estimates. The estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognized in the period in which the estimate is revised, if the revision affects only that period, or in the period of the revision and future periods if the revision affects both current and future periods. The estimates and assumptions which have a significant risk of causing a material adjustment to the carrying amount of assets and liabilities are outlined below. <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 36px"> </td> <td style="width: 24px">(1)</td> <td>Impairment and useful life determination of intellectual property rights</td></tr> </table> The Company’s intangible assets include intellectual property (‘IP’) rights transferred to the Company as part of the February 2023 common-control transaction described in Note 7. Management exercised significant judgment in determining that the Company's intellectual property rights have a definite useful life of 10 years. In making this assessment, management considered the nature of the underlying technology platform, expected product life cycles, anticipated commercialization timelines, the pace of technological change within the industry, competitive developments, and the period over which the intellectual property is expected to generate economic benefits for the Company. The intellectual property rights are amortised on a straight-line basis over their estimated useful life of ten years commencing on 6 February 2023. The assessment also considered the legal and economic environment in which the intellectual property operates, including statutory protection periods, the expected ability to maintain and enhance the technology through ongoing development activities, and the likelihood that future technological advancements may diminish the value of the existing intellectual property over time. Based on these factors, management concluded that a 10-year useful life represents the period over which the intellectual property is expected to contribute to future cash flows. The intellectual property rights are amortized on a systematic basis over their estimated useful life of 10 years and are reviewed at least annually to determine whether events or changes in circumstances warrant a revision to the useful life estimate or indicate impairment. The Company assesses its intellectual property rights for impairment whenever events or changes in circumstances indicate that the carrying amount may not be recoverable, in accordance with IAS 36. The impairment assessment involves estimating the recoverable amount of the cash-generating unit ("CGU") to which the IP rights belong. Management exercised significant judgment in identifying the appropriate CGU to which the Company's intellectual property assets are allocated for impairment testing purposes. This judgment required consideration of how management monitors operations, the level of interdependence between products and services, and the manner in which future cash flows are generated. Management also exercised significant judgment in determining key assumptions used in any impairment assessment, including forecast cash flows, revenue growth rates, the structure of future licensing arrangements, product launch dates, expected operating margins, long-term growth rates and pre-tax discount rates. Changes in these assumptions could affect the recoverable amount of the CGU and result in the recognition of an impairment loss. Management has determined that, based on the assumptions applied as of the reporting date, there were no indicators that the carrying amount of the related assets exceeded their recoverable amount <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 36px"> </td> <td style="width: 24px">(2)</td> <td>Going concern basis</td></tr> </table> Management has made an assessment of the Company’s ability to continue as a going concern and exercised significant judgment in concluding that the going concern basis of accounting is appropriate. In making this assessment, management considered the Company’s recurring losses, its limited cash balance at year end, its forecasted cash position to meet obligations as they fall due and its dependence on financial support from its principal shareholder and CEO to fund operations. Management also considered the receipt of a letter the Company’s CEO to provide financial support for a period of at least twelve months from the date that these consolidated financial statements are authorized, as well as considering the Company's expected commercialization of its product portfolio, potential direct product revenues, potential regional licensing and distribution arrangements, financing arrangements entered into subsequent to December 31, 2025 and the continuing financial support of its principal shareholder and CEO.. Based on all the relevant factors, management has concluded that no material uncertainties exist that would cast significant doubt on the Company’s ability to continue as a going concern.

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 36px">4</td> <td>Operating loss – as restated</td></tr> </table> <table cellpadding="0" cellspacing="0" id="xdx_889_ecustom--ScheduleOfOperatingLossTableTextBlock_z0u0MXHxiVel" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Operating loss (Details)"> <tr style="vertical-align: bottom"> <td>Schedule of operating loss</td> <td> </td> <td colspan="2" id="xdx_49F_20250101__20251231_zwChdLnpcx7T" style="text-align: center"> </td> <td> </td> <td> </td> <td colspan="2" id="xdx_499_20240101__20241231_zPw5S1ROpivT" style="text-align: center"> </td> <td> </td></tr> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">2025</td> <td> </td> <td> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">2024</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td colspan="2" style="text-align: center">€</td> <td> </td> <td> </td> <td colspan="2" style="text-align: center">€</td> <td> </td></tr> <tr id="xdx_402_ecustom--OperatingLossAbstract_iB_zpEVy9mb7gmi" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Operating loss for the year is stated after charging/(crediting):</td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr id="xdx_406_eifrs-full--Amortisation_zlqkprTgM7VD" style="vertical-align: bottom; background-color: White"> <td>Amortisation</td> <td> </td> <td> </td> <td style="text-align: right">304,830</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">304,830</td> <td> </td></tr> <tr id="xdx_40C_eifrs-full--OtherGainsLosses_iN_di_zI3tnUHurs1_zbeSWep2iIk9" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 66%">Exchange loss/gains</td> <td style="width: 2%"> </td> <td style="width: 1%"> </td> <td style="width: 13%; text-align: right">220</td> <td style="width: 1%"> </td> <td style="width: 2%"> </td> <td style="width: 1%"> </td> <td style="width: 13%; text-align: right">(2</td> <td style="width: 1%">)</td></tr> <tr id="xdx_405_eifrs-full--ResearchAndDevelopmentExpense_d0_zho87vxHVsZ4" style="vertical-align: bottom; background-color: White"> <td>Research and development costs</td> <td> </td> <td style="border-bottom: black 2.25pt double"> </td> <td style="border-bottom: black 2.25pt double; text-align: right">–</td> <td> </td> <td> </td> <td style="border-bottom: black 2.25pt double"> </td> <td style="border-bottom: black 2.25pt double; text-align: right">8,159</td> <td> </td></tr> </table>

<table cellpadding="0" cellspacing="0" id="xdx_889_ecustom--ScheduleOfOperatingLossTableTextBlock_z0u0MXHxiVel" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Operating loss (Details)"> <tr style="vertical-align: bottom"> <td>Schedule of operating loss</td> <td> </td> <td colspan="2" id="xdx_49F_20250101__20251231_zwChdLnpcx7T" style="text-align: center"> </td> <td> </td> <td> </td> <td colspan="2" id="xdx_499_20240101__20241231_zPw5S1ROpivT" style="text-align: center"> </td> <td> </td></tr> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">2025</td> <td> </td> <td> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">2024</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td colspan="2" style="text-align: center">€</td> <td> </td> <td> </td> <td colspan="2" style="text-align: center">€</td> <td> </td></tr> <tr id="xdx_402_ecustom--OperatingLossAbstract_iB_zpEVy9mb7gmi" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Operating loss for the year is stated after charging/(crediting):</td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr id="xdx_406_eifrs-full--Amortisation_zlqkprTgM7VD" style="vertical-align: bottom; background-color: White"> <td>Amortisation</td> <td> </td> <td> </td> <td style="text-align: right">304,830</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">304,830</td> <td> </td></tr> <tr id="xdx_40C_eifrs-full--OtherGainsLosses_iN_di_zI3tnUHurs1_zbeSWep2iIk9" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 66%">Exchange loss/gains</td> <td style="width: 2%"> </td> <td style="width: 1%"> </td> <td style="width: 13%; text-align: right">220</td> <td style="width: 1%"> </td> <td style="width: 2%"> </td> <td style="width: 1%"> </td> <td style="width: 13%; text-align: right">(2</td> <td style="width: 1%">)</td></tr> <tr id="xdx_405_eifrs-full--ResearchAndDevelopmentExpense_d0_zho87vxHVsZ4" style="vertical-align: bottom; background-color: White"> <td>Research and development costs</td> <td> </td> <td style="border-bottom: black 2.25pt double"> </td> <td style="border-bottom: black 2.25pt double; text-align: right">–</td> <td> </td> <td> </td> <td style="border-bottom: black 2.25pt double"> </td> <td style="border-bottom: black 2.25pt double; text-align: right">8,159</td> <td> </td></tr> </table>

304830

-220

8159

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 36px">5</td> <td>Employees</td></tr> </table> The average monthly number of people (excluding directors) employed by the Company during the year was: <table cellpadding="0" cellspacing="0" id="xdx_898_ecustom--ScheduleOfEmployeesTableTextBlock_zBguDwRYy1b4" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Employees (Details)"> <tr style="vertical-align: bottom"> <td>Schedule of employees of excluding directors</td> <td> </td> <td> </td> <td style="text-align: center"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: center"> </td> <td> </td></tr> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td> </td> <td style="border-bottom: black 1pt solid; text-align: center">2025</td> <td> </td> <td> </td> <td> </td> <td style="border-bottom: black 1pt solid; text-align: center">2024</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td> </td> <td style="text-align: center">Number</td> <td> </td> <td> </td> <td> </td> <td style="text-align: center">Number</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 66%">Total</td> <td style="width: 2%"> </td> <td style="width: 1%"> </td> <td id="xdx_98B_edei--EntityNumberOfEmployees_iI_d0_uDecimal_c20251231_zKa7uDdK9mv9" style="border-bottom: black 2.25pt double; width: 13%; text-align: right" title="Number of persons employed">–</td> <td style="width: 1%"> </td> <td style="width: 2%"> </td> <td style="width: 1%"> </td> <td id="xdx_981_edei--EntityNumberOfEmployees_iI_d0_uDecimal_c20241231_zQTwEY8Qaqdi" style="border-bottom: black 2.25pt double; width: 13%; text-align: right" title="Number of persons employed">–</td> <td style="width: 1%"> </td></tr> </table>

<table cellpadding="0" cellspacing="0" id="xdx_898_ecustom--ScheduleOfEmployeesTableTextBlock_zBguDwRYy1b4" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Employees (Details)"> <tr style="vertical-align: bottom"> <td>Schedule of employees of excluding directors</td> <td> </td> <td> </td> <td style="text-align: center"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: center"> </td> <td> </td></tr> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td> </td> <td style="border-bottom: black 1pt solid; text-align: center">2025</td> <td> </td> <td> </td> <td> </td> <td style="border-bottom: black 1pt solid; text-align: center">2024</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td> </td> <td style="text-align: center">Number</td> <td> </td> <td> </td> <td> </td> <td style="text-align: center">Number</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 66%">Total</td> <td style="width: 2%"> </td> <td style="width: 1%"> </td> <td id="xdx_98B_edei--EntityNumberOfEmployees_iI_d0_uDecimal_c20251231_zKa7uDdK9mv9" style="border-bottom: black 2.25pt double; width: 13%; text-align: right" title="Number of persons employed">–</td> <td style="width: 1%"> </td> <td style="width: 2%"> </td> <td style="width: 1%"> </td> <td id="xdx_981_edei--EntityNumberOfEmployees_iI_d0_uDecimal_c20241231_zQTwEY8Qaqdi" style="border-bottom: black 2.25pt double; width: 13%; text-align: right" title="Number of persons employed">–</td> <td style="width: 1%"> </td></tr> </table> 0 0

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 36px">6</td> <td>Income tax expense – as restated</td></tr> </table> The Company’s effective tax rate was 0% for the years ended December 31, 2025 and 2024 and can be reconciled to its pre-tax Operating loss as follows: <table cellpadding="0" cellspacing="0" id="xdx_892_ecustom--ScheduleOfIncomeTaxExpenseBenefitTableTextBlock_zs6RLyrAEQeV" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Income tax expense (Details)"> <tr style="vertical-align: bottom"> <td>Schedule of income tax expenses</td> <td> </td> <td> </td> <td id="xdx_49C_20250101__20251231_zIIbGxPIP1rc" style="text-align: center"> </td> <td> </td> <td> </td> <td> </td> <td id="xdx_497_20240101__20241231_zTwOPGSltSDa" style="text-align: center"> </td> <td> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td> <td> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">2025</td> <td> </td> <td> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">2024</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td> <td> </td> <td colspan="2" style="text-align: center">€</td> <td> </td> <td> </td> <td colspan="2" style="text-align: center">€</td> <td> </td></tr> <tr id="xdx_40A_eifrs-full--ProfitLoss_zMXJ7cfk7byH" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 66%">Operating loss before taxation</td> <td style="width: 2%"> </td> <td style="border-bottom: black 1pt solid; width: 1%"> </td> <td style="border-bottom: black 1pt solid; width: 13%; text-align: right">(1,128,807</td> <td style="width: 1%">)</td> <td style="width: 2%"> </td> <td style="border-bottom: black 1pt solid; width: 1%"> </td> <td style="border-bottom: black 1pt solid; width: 13%; text-align: right">(1,625,183</td> <td style="width: 1%">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Expected tax credit based on a corporation tax rate of 12.50% </td> <td> </td> <td> </td> <td style="text-align: right">141,101</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">203,148</td> <td> </td></tr> <tr id="xdx_407_eifrs-full--TaxBenefitArisingFromPreviouslyUnrecognisedTaxLossTaxCreditOrTemporaryDifferenceOfPriorPeriodUsedToReduceCurrentTaxExpense_iN_di_zzhHGJMe4rhW" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Tax benefits not recognized</td> <td> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">(141,101</td> <td>)</td> <td> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">(203,148</td> <td>)</td></tr> <tr id="xdx_40F_eifrs-full--IncomeTaxExpenseContinuingOperations_d0_zHmqpz0g3fnW" style="vertical-align: bottom; background-color: White"> <td>Tax expense, Net deferred tax asset for the year</td> <td> </td> <td style="border-bottom: black 2.25pt double"> </td> <td style="border-bottom: black 2.25pt double; text-align: right">–</td> <td> </td> <td> </td> <td style="border-bottom: black 2.25pt double"> </td> <td style="border-bottom: black 2.25pt double; text-align: right">–</td> <td> </td></tr> </table>

<table cellpadding="0" cellspacing="0" id="xdx_892_ecustom--ScheduleOfIncomeTaxExpenseBenefitTableTextBlock_zs6RLyrAEQeV" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Income tax expense (Details)"> <tr style="vertical-align: bottom"> <td>Schedule of income tax expenses</td> <td> </td> <td> </td> <td id="xdx_49C_20250101__20251231_zIIbGxPIP1rc" style="text-align: center"> </td> <td> </td> <td> </td> <td> </td> <td id="xdx_497_20240101__20241231_zTwOPGSltSDa" style="text-align: center"> </td> <td> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td> <td> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">2025</td> <td> </td> <td> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">2024</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td> <td> </td> <td colspan="2" style="text-align: center">€</td> <td> </td> <td> </td> <td colspan="2" style="text-align: center">€</td> <td> </td></tr> <tr id="xdx_40A_eifrs-full--ProfitLoss_zMXJ7cfk7byH" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 66%">Operating loss before taxation</td> <td style="width: 2%"> </td> <td style="border-bottom: black 1pt solid; width: 1%"> </td> <td style="border-bottom: black 1pt solid; width: 13%; text-align: right">(1,128,807</td> <td style="width: 1%">)</td> <td style="width: 2%"> </td> <td style="border-bottom: black 1pt solid; width: 1%"> </td> <td style="border-bottom: black 1pt solid; width: 13%; text-align: right">(1,625,183</td> <td style="width: 1%">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Expected tax credit based on a corporation tax rate of 12.50% </td> <td> </td> <td> </td> <td style="text-align: right">141,101</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">203,148</td> <td> </td></tr> <tr id="xdx_407_eifrs-full--TaxBenefitArisingFromPreviouslyUnrecognisedTaxLossTaxCreditOrTemporaryDifferenceOfPriorPeriodUsedToReduceCurrentTaxExpense_iN_di_zzhHGJMe4rhW" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Tax benefits not recognized</td> <td> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">(141,101</td> <td>)</td> <td> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">(203,148</td> <td>)</td></tr> <tr id="xdx_40F_eifrs-full--IncomeTaxExpenseContinuingOperations_d0_zHmqpz0g3fnW" style="vertical-align: bottom; background-color: White"> <td>Tax expense, Net deferred tax asset for the year</td> <td> </td> <td style="border-bottom: black 2.25pt double"> </td> <td style="border-bottom: black 2.25pt double; text-align: right">–</td> <td> </td> <td> </td> <td style="border-bottom: black 2.25pt double"> </td> <td style="border-bottom: black 2.25pt double; text-align: right">–</td> <td> </td></tr> </table>

-1128807

-1625183

141101

203148

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 36px">7</td> <td>Intangible assets – as restated </td></tr> </table> Common-Control Transfer and Initial Recognition In February 2023, the Company completed a transaction under common control whereby intellectual property was transferred from Davion Healthcare Limited (United Kingdom) to the Company. For accounting purposes, the transfer has been accounted for as a transfer between entities under common control because control of the intellectual property remained unchanged before and after the transaction. Accordingly, the intellectual property has been recognised at the predecessor entity's carrying amount immediately prior to the transfer, rather than at the contractual consideration or any fair value. The carrying amount represents the historical carrying value of the intellectual property as recognised in the financial statements of Davion Healthcare Limited (United Kingdom), with continuity of the predecessor's accounting basis. The Company has therefore revised the historical accounting treatment to reflect the predecessor carrying value of the intellectual property from the date of transfer. Subsequent to initial recognition under this accounting basis, the intellectual property is amortised over its estimated useful economic life of ten years commencing from the date of transfer on 6 February 2023, with amortisation recognised in profit or loss. This revision reflects the accounting basis required for these financial statements and does not affect the legal ownership of the intellectual property, the underlying transfer agreement, the consideration issued, or the Company's commercial rights to develop and exploit the intellectual property. Subsequent Expenditure Since the transfer of the intellectual property rights, the Company invested further in the enhancement and development of the intellectual property; however, none of these costs met the recognition criteria under IAS 38 due to there being no active market in accordance with “IAS” 38. These costs primarily related to technical refinement and commercialization readiness. Footflow and ThermaDerm were added to the Company's product portfolio and the regulatory registration for BreastCheck, Testic, Footflow and ThermaDerm was established with the U.S. Food and Drug Administration (FDA), the EU under the CE mark, and the UK Regulatory authority under the UKCA mark, enabling future commercialisation of the related products. In 2025, the Company entered into an intellectual property licensing arrangement with NeuRX Health Inc. (“NeuRX”) which contemplated future license and royalty revenues. As a result, the Company adopted an accounting policy for revenue recognition in accordance with IFRS 15 – Revenue from Contracts with Customers. No revenue was recognised under the arrangement during the year ended December 31, 2025. Subsequent to the reporting period, the Company terminated the NeuRX agreement. See Subsequent Events for further information. The Company’s intellectual property rights at December 31, 2025 and 2024 are as follows: <table cellpadding="0" cellspacing="0" id="xdx_89F_ecustom--DisclosureOfIntellectualPropertyTableTextBlock_pn3n3_ztYC3NYcFiwL" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Intangible assets (Details)"> <tr style="vertical-align: bottom"> <td>Schedule of intellectual property rights</td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> </tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td> <td> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">Predecessor Carry Amount </td> <td> </td> </tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td> <td> </td> <td colspan="2" style="text-align: center">€</td> <td> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 83%">BreastCheck IP Rights</td> <td style="width: 2%"> </td> <td style="width: 1%"> </td> <td style="width: 13%; text-align: right"><span id="xdx_908_eifrs-full--IntangibleAssetFairValueUsedAsDeemedCost_iI_pp0p0_c20251231__ifrs-full--ClassesOfIntangibleAssetsOtherThanGoodwillAxis__custom--BreastCheckIPRightsMember_zCJMcWpdcOea" title="Fair value of the intangible asset"><span id="xdx_906_eifrs-full--IntangibleAssetFairValueUsedAsDeemedCost_iI_pp0p0_c20241231__ifrs-full--ClassesOfIntangibleAssetsOtherThanGoodwillAxis__custom--BreastCheckIPRightsMember_zY0SHA9r06di" title="Fair value of the intangible asset">2,813,819</td> <td style="width: 1%"> </td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td>Tricos IP Rights</td> <td> </td> <td> </td> <td style="text-align: right"><span id="xdx_905_eifrs-full--IntangibleAssetFairValueUsedAsDeemedCost_c20251231__ifrs-full--ClassesOfIntangibleAssetsOtherThanGoodwillAxis__custom--TricosIPRightsMember_pp0p0_zpW2xBGV4tEV" title="fair value of the intangible asset"><span id="xdx_902_eifrs-full--IntangibleAssetFairValueUsedAsDeemedCost_iI_pp0p0_c20241231__ifrs-full--ClassesOfIntangibleAssetsOtherThanGoodwillAxis__custom--TricosIPRightsMember_zCMkDLRxD6Cb" title="Fair value of the intangible asset">46,896</td> <td> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Testic IP Rights</td> <td> </td> <td> </td> <td style="text-align: right"><span id="xdx_902_eifrs-full--IntangibleAssetFairValueUsedAsDeemedCost_iI_pp0p0_c20251231__ifrs-full--ClassesOfIntangibleAssetsOtherThanGoodwillAxis__custom--TesticIPRightsMember_zVfpMVflsHMe" title="fair value of the intangible asset"><span id="xdx_90D_eifrs-full--IntangibleAssetFairValueUsedAsDeemedCost_iI_pp0p0_c20241231__ifrs-full--ClassesOfIntangibleAssetsOtherThanGoodwillAxis__custom--TesticIPRightsMember_zB6FSmpk1xKv" title="Fair value of the intangible asset">46,896</td> <td> </td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td>Davion Masks IP Rights</td> <td> </td> <td> </td> <td style="text-align: right"><span id="xdx_906_eifrs-full--IntangibleAssetFairValueUsedAsDeemedCost_iI_pp0p0_c20251231__ifrs-full--ClassesOfIntangibleAssetsOtherThanGoodwillAxis__custom--DavionMasksIPRightsMember_zSt8vq2Ybn8_zvHeAUnnRyJx" title="fair value of the intangible asset"><span id="xdx_902_eifrs-full--IntangibleAssetFairValueUsedAsDeemedCost_iI_pp0p0_c20241231__ifrs-full--ClassesOfIntangibleAssetsOtherThanGoodwillAxis__custom--DavionMasksIPRightsMember_zb78egf6Ijuw" title="Fair value of the intangible asset">70,345</td> <td> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Bio-Genex IP Rights</td> <td> </td> <td> </td> <td style="text-align: right"><span id="xdx_909_eifrs-full--IntangibleAssetFairValueUsedAsDeemedCost_c20251231__ifrs-full--ClassesOfIntangibleAssetsOtherThanGoodwillAxis__custom--BioGenexIPRightsMember_pp0p0_zxQa9fPmMxe9" title="fair value of the intangible asset"><span id="xdx_908_eifrs-full--IntangibleAssetFairValueUsedAsDeemedCost_iI_pp0p0_c20241231__ifrs-full--ClassesOfIntangibleAssetsOtherThanGoodwillAxis__custom--BioGenexIPRightsMember_zxVcPwve3din" title="Fair value of the intangible asset">46,896</td> <td> </td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td>Merit IP Rights</td> <td> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right"><span id="xdx_908_eifrs-full--IntangibleAssetFairValueUsedAsDeemedCost_iI_pp0p0_c20251231__ifrs-full--ClassesOfIntangibleAssetsOtherThanGoodwillAxis__custom--MeritIPRightsMember_zwQjEj415w5g" title="fair value of the intangible asset"><span id="xdx_903_eifrs-full--IntangibleAssetFairValueUsedAsDeemedCost_iI_pp0p0_c20241231__ifrs-full--ClassesOfIntangibleAssetsOtherThanGoodwillAxis__custom--MeritIPRightsMember_zt0PXj2VICuE" title="Fair value of the intangible asset">23,452</td> <td> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Total</td> <td> </td> <td style="border-bottom: black 2.25pt double"> </td> <td style="border-bottom: black 2.25pt double; text-align: right">3,048,304</td> <td> </td> </tr> </table> <table cellpadding="0" cellspacing="0" id="xdx_88A_eifrs-full--DisclosureOfIntangibleAssetsTable_zATcwQkJSmA9" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse" summary="xdx: Disclosure - Intangible Assets (Details - Rollforward)"> <tr style="vertical-align: bottom"> <td style="text-align: left">Rollforward of intangible assets</td> <td> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">2025</td> <td> </td> <td> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">2024</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td> <td> </td> <td colspan="2" style="text-align: center">€</td> <td> </td> <td> </td> <td colspan="2" style="text-align: center">€</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 66%">Carrying value at beginning of year</td> <td style="width: 2%"> </td> <td style="width: 1%"> </td> <td id="xdx_98D_eifrs-full--IntangibleAssetsOtherThanGoodwill_iI_c20241231_zjM4rOkjBV3Z" style="width: 13%; text-align: right" title="Intangible assets, balance">2,489,448</td> <td style="width: 1%"> </td> <td style="width: 2%"> </td> <td style="width: 1%"> </td> <td id="xdx_988_eifrs-full--IntangibleAssetsOtherThanGoodwill_iI_c20231231_zzeK1Jv4QFkq" style="width: 13%; text-align: right" title="Intangible assets, balance">2,794,279</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Additions</td> <td> </td> <td> </td> <td id="xdx_989_eifrs-full--AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill_d0_c20250101__20251231_zv0jpX5JajCw" style="text-align: right" title="Additions">–</td> <td> </td> <td> </td> <td> </td> <td id="xdx_986_eifrs-full--AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill_d0_c20240101__20241231_z61Y1KDnY4oG" style="text-align: right" title="Additions">–</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Amortization charge</td> <td> </td> <td> </td> <td id="xdx_98F_eifrs-full--AmortisationIntangibleAssetsOtherThanGoodwill_iN_di_c20250101__20251231_z5Cm0HCeqv6p" style="text-align: right" title="Amortization">(304,830</td> <td>)</td> <td> </td> <td> </td> <td id="xdx_98D_eifrs-full--AmortisationIntangibleAssetsOtherThanGoodwill_iN_di_c20240101__20241231_zUAkUTdR2F2O" style="text-align: right" title="Amortization">(304,830</td> <td>)</td></tr> <tr style="vertical-align: bottom"> <td>Impairment loss</td> <td> </td> <td> </td> <td id="xdx_984_eifrs-full--ImpairmentLossRecognisedInOtherComprehensiveIncomeIntangibleAssetsOtherThanGoodwill_d0_c20250101__20251231_z5HtUp6tvJpy" style="text-align: right" title="Impairment loss">–</td> <td> </td> <td> </td> <td> </td> <td id="xdx_980_eifrs-full--ImpairmentLossRecognisedInOtherComprehensiveIncomeIntangibleAssetsOtherThanGoodwill_d0_c20240101__20241231_zNmkA5X6UzxT" style="text-align: right" title="Impairment loss">–</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Foreign currency translation adjustment</td> <td> </td> <td style="border-bottom: black 1pt solid"> </td> <td id="xdx_98F_eifrs-full--ChangesInIntangibleAssetsOtherThanGoodwill_d0_c20250101__20251231_zAS1hTWMFTds" style="border-bottom: black 1pt solid; text-align: right" title="Foreign currency translation adjustment">–</td> <td> </td> <td> </td> <td style="border-bottom: black 1pt solid"> </td> <td id="xdx_98E_eifrs-full--ChangesInIntangibleAssetsOtherThanGoodwill_d0_c20240101__20241231_zTazvkV2ibrh" style="border-bottom: black 1pt solid; text-align: right" title="Foreign currency translation adjustment">–</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Carrying value at end of year</td> <td> </td> <td style="border-bottom: black 2.25pt double"> </td> <td id="xdx_98F_eifrs-full--IntangibleAssetsOtherThanGoodwill_iI_c20251231_zt2pFvu5RXwc" style="border-bottom: black 2.25pt double; text-align: right" title="Intangible assets, balance">2,184,618</td> <td> </td> <td> </td> <td style="border-bottom: black 2.25pt double"> </td> <td id="xdx_98D_eifrs-full--IntangibleAssetsOtherThanGoodwill_iI_c20241231_zgrE41TtLxaK" style="border-bottom: black 2.25pt double; text-align: right" title="Intangible assets, balance">2,489,448</td> <td> </td></tr> </table> Useful life assessment The Company's intellectual property consists of proprietary technologies, patents and related know-how underlying the Company's testing platform. Management has determined that the intellectual property has a finite useful life of 10 years. In assessing the useful life, management considered the expected period over which the technology is anticipated to contribute to future cash flows, the pace of technological developments within the industry, the expected commercial life of the underlying products and the legal and economic characteristics of the intellectual property portfolio. The intellectual property is initially recognised at cost and is subsequently measured using the cost model. The asset is amortised on a straight-line basis over its estimated useful life of 10 years, which management believes reflects the pattern in which the future economic benefits of the asset are expected to be consumed. The useful life and amortisation method are reviewed at least annually and revised prospectively where appropriate. The intellectual property is also assessed for impairment whenever indicators of impairment exist. Impairment assessment The Company performed its annual impairment assessment using a value-in-use model, which incorporates projected future cash flows that are expected to be generated through direct commercialization, licensing and distribution arrangements. licensing revenues and related royalties associated with the Company’s intellectual property that are yet to be launched. The Company’s assessment is based in part on management’s evaluation, which incorporates information derived from a third party valuation prepared for inter management’s internal use, together with externally observable evidence, including the execution of an arm’s length licensing agreement with a third party. While management has applied judgment in assessing the methodologies and assumptions utilized by the third party valuation specialist, the Company does not rely on internal equity valuations, implied market capitalization or internally generated valuation multiples in assessing recoverability. References to assumptions for estimating cash flows, discount rates and valuation techniques are solely for purposes of impairment testing under IAS 36 and do not represent a fair value measurement under IFRS 13. For 2025, the key assumptions used in our discounted cash model included: <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 0.25in"> </td> <td style="width: 0.25in; text-align: justify">·</td> <td style="text-align: justify">management’s projected cash flows for the period 2026 through 2031, including revenues and operating margins from contractual license terms and expected future product launches.</td></tr> <tr style="vertical-align: top"> <td> </td> <td style="text-align: justify">·</td> <td style="text-align: justify">a terminal value calculated using a 2.5x EBIT multiple</td></tr> <tr style="vertical-align: top"> <td> </td> <td style="text-align: justify">·</td> <td style="text-align: justify">a progressively increasing discount rate reflecting the early-stage nature and risk of the Company’s product commercialization strategy 30% - 47.5%.</td></tr> </table> The impairment test requires management to make significant estimates and assumptions regarding projected cash flows, inclusive of product commercialization timelines, expected market penetration, licensing revenue growth, royalty structures, as well as risk adjusted discount rates reflecting the risk profile of the business. Management's forecasts reflect the Company's current commercialization strategy and assumptions regarding product launch timing, market penetration, direct sales and potential third-party manufacturing, licensing and distribution arrangements. These assumptions involve significant judgement and actual results may differ materially from the estimates used. Management performed sensitivity analysis on the underlying key assumptions related to the projected cash flows and the risk adjusted discount rates. Management has determined that, while the recoverable amount of the CGU is sensitive to changes in certain key assumptions, reasonably possible changes in those assumptions, based on management’s assessment, would not be expected to result in the carrying amount of the CGU exceeding its recoverable amount as of the reporting date. Based on the impairment testing performed, the recoverable amount of the intellectual property exceeded the carrying amount of the intellectual property at December 31, 2025. Accordingly, no indicators of impairment were identified and as a result, no impairment loss was recorded at December 31, 2025 and 2024.

<table cellpadding="0" cellspacing="0" id="xdx_89F_ecustom--DisclosureOfIntellectualPropertyTableTextBlock_pn3n3_ztYC3NYcFiwL" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Intangible assets (Details)"> <tr style="vertical-align: bottom"> <td>Schedule of intellectual property rights</td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> </tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td> <td> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">Predecessor Carry Amount </td> <td> </td> </tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td> <td> </td> <td colspan="2" style="text-align: center">€</td> <td> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 83%">BreastCheck IP Rights</td> <td style="width: 2%"> </td> <td style="width: 1%"> </td> <td style="width: 13%; text-align: right"><span id="xdx_908_eifrs-full--IntangibleAssetFairValueUsedAsDeemedCost_iI_pp0p0_c20251231__ifrs-full--ClassesOfIntangibleAssetsOtherThanGoodwillAxis__custom--BreastCheckIPRightsMember_zCJMcWpdcOea" title="Fair value of the intangible asset"><span id="xdx_906_eifrs-full--IntangibleAssetFairValueUsedAsDeemedCost_iI_pp0p0_c20241231__ifrs-full--ClassesOfIntangibleAssetsOtherThanGoodwillAxis__custom--BreastCheckIPRightsMember_zY0SHA9r06di" title="Fair value of the intangible asset">2,813,819</td> <td style="width: 1%"> </td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td>Tricos IP Rights</td> <td> </td> <td> </td> <td style="text-align: right"><span id="xdx_905_eifrs-full--IntangibleAssetFairValueUsedAsDeemedCost_c20251231__ifrs-full--ClassesOfIntangibleAssetsOtherThanGoodwillAxis__custom--TricosIPRightsMember_pp0p0_zpW2xBGV4tEV" title="fair value of the intangible asset"><span id="xdx_902_eifrs-full--IntangibleAssetFairValueUsedAsDeemedCost_iI_pp0p0_c20241231__ifrs-full--ClassesOfIntangibleAssetsOtherThanGoodwillAxis__custom--TricosIPRightsMember_zCMkDLRxD6Cb" title="Fair value of the intangible asset">46,896</td> <td> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Testic IP Rights</td> <td> </td> <td> </td> <td style="text-align: right"><span id="xdx_902_eifrs-full--IntangibleAssetFairValueUsedAsDeemedCost_iI_pp0p0_c20251231__ifrs-full--ClassesOfIntangibleAssetsOtherThanGoodwillAxis__custom--TesticIPRightsMember_zVfpMVflsHMe" title="fair value of the intangible asset"><span id="xdx_90D_eifrs-full--IntangibleAssetFairValueUsedAsDeemedCost_iI_pp0p0_c20241231__ifrs-full--ClassesOfIntangibleAssetsOtherThanGoodwillAxis__custom--TesticIPRightsMember_zB6FSmpk1xKv" title="Fair value of the intangible asset">46,896</td> <td> </td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td>Davion Masks IP Rights</td> <td> </td> <td> </td> <td style="text-align: right"><span id="xdx_906_eifrs-full--IntangibleAssetFairValueUsedAsDeemedCost_iI_pp0p0_c20251231__ifrs-full--ClassesOfIntangibleAssetsOtherThanGoodwillAxis__custom--DavionMasksIPRightsMember_zSt8vq2Ybn8_zvHeAUnnRyJx" title="fair value of the intangible asset"><span id="xdx_902_eifrs-full--IntangibleAssetFairValueUsedAsDeemedCost_iI_pp0p0_c20241231__ifrs-full--ClassesOfIntangibleAssetsOtherThanGoodwillAxis__custom--DavionMasksIPRightsMember_zb78egf6Ijuw" title="Fair value of the intangible asset">70,345</td> <td> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Bio-Genex IP Rights</td> <td> </td> <td> </td> <td style="text-align: right"><span id="xdx_909_eifrs-full--IntangibleAssetFairValueUsedAsDeemedCost_c20251231__ifrs-full--ClassesOfIntangibleAssetsOtherThanGoodwillAxis__custom--BioGenexIPRightsMember_pp0p0_zxQa9fPmMxe9" title="fair value of the intangible asset"><span id="xdx_908_eifrs-full--IntangibleAssetFairValueUsedAsDeemedCost_iI_pp0p0_c20241231__ifrs-full--ClassesOfIntangibleAssetsOtherThanGoodwillAxis__custom--BioGenexIPRightsMember_zxVcPwve3din" title="Fair value of the intangible asset">46,896</td> <td> </td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td>Merit IP Rights</td> <td> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right"><span id="xdx_908_eifrs-full--IntangibleAssetFairValueUsedAsDeemedCost_iI_pp0p0_c20251231__ifrs-full--ClassesOfIntangibleAssetsOtherThanGoodwillAxis__custom--MeritIPRightsMember_zwQjEj415w5g" title="fair value of the intangible asset"><span id="xdx_903_eifrs-full--IntangibleAssetFairValueUsedAsDeemedCost_iI_pp0p0_c20241231__ifrs-full--ClassesOfIntangibleAssetsOtherThanGoodwillAxis__custom--MeritIPRightsMember_zt0PXj2VICuE" title="Fair value of the intangible asset">23,452</td> <td> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Total</td> <td> </td> <td style="border-bottom: black 2.25pt double"> </td> <td style="border-bottom: black 2.25pt double; text-align: right">3,048,304</td> <td> </td> </tr> </table>

2813819

46896

70345

46896

23452

3048304

2489448

2794279

304830

2184618

2489448

0.30

0.475

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 36px">8</td> <td>Credit risk</td></tr> </table> Credit risk arises when a failure by counterparties to discharge their obligations could reduce the amount of future cash inflows from financial assets on hand at the reporting date. The Company has policies in place to ensure that intellectual property licenses are made to customers with an appropriate credit history and monitors on a continuous basis the ageing profile of its receivables. Cash balances are held with high credit quality financial institutions, and the Company has policies to limit the amount of credit exposure to any financial institution. Except as detailed below, the carrying amount of financial assets recorded in the consolidated financial statements, which is net of impairment losses, if any, represents the Company’s maximum exposure to credit risk. Maximum credit risk <table cellpadding="0" cellspacing="0" id="xdx_89E_ecustom--DisclosureOfMaximumCreditRiskExposureExplanatory_zZ5CTcUfMAF8" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Credit risk (Details)"> <tr style="vertical-align: bottom"> <td>Schedule of maximum credit risk</td><td> </td> <td colspan="2" id="xdx_49C_20251231_ztS1DIXrG3wS" style="text-align: center"> </td><td> </td><td> </td> <td colspan="2" id="xdx_495_20241231_zxCcEd83Xasj" style="text-align: center"> </td><td> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="width: 66%; text-align: center"> </td><td style="width: 2%; font-weight: bold"> </td> <td style="width: 1%; font-weight: bold; text-align: left"> </td><td style="width: 13%; font-weight: bold; text-align: center">€</td><td style="width: 1%; font-weight: bold; text-align: left"> </td><td style="width: 2%; font-weight: bold"> </td> <td style="width: 1%; font-weight: bold; text-align: left"> </td><td style="width: 13%; font-weight: bold; text-align: center">€</td><td style="width: 1%; font-weight: bold; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: center"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40F_eifrs-full--CashAndCashEquivalents_iI_d0_zo0kiIcyBMCO" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Cash and cash equivalents</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">1,058</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">11</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> The Company does not hold any collateral or other credit enhancements to cover this credit risk.

<table cellpadding="0" cellspacing="0" id="xdx_89E_ecustom--DisclosureOfMaximumCreditRiskExposureExplanatory_zZ5CTcUfMAF8" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Credit risk (Details)"> <tr style="vertical-align: bottom"> <td>Schedule of maximum credit risk</td><td> </td> <td colspan="2" id="xdx_49C_20251231_ztS1DIXrG3wS" style="text-align: center"> </td><td> </td><td> </td> <td colspan="2" id="xdx_495_20241231_zxCcEd83Xasj" style="text-align: center"> </td><td> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="width: 66%; text-align: center"> </td><td style="width: 2%; font-weight: bold"> </td> <td style="width: 1%; font-weight: bold; text-align: left"> </td><td style="width: 13%; font-weight: bold; text-align: center">€</td><td style="width: 1%; font-weight: bold; text-align: left"> </td><td style="width: 2%; font-weight: bold"> </td> <td style="width: 1%; font-weight: bold; text-align: left"> </td><td style="width: 13%; font-weight: bold; text-align: center">€</td><td style="width: 1%; font-weight: bold; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: center"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40F_eifrs-full--CashAndCashEquivalents_iI_d0_zo0kiIcyBMCO" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Cash and cash equivalents</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">1,058</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">11</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> The Company does not hold any collateral or other credit enhancements to cover this credit risk.

1058

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 36px">9</td> <td>Trade receivables - credit risk</td></tr> </table> Fair value of trade receivables The directors consider that the carrying amount of trade and other receivables is approximately equal to their fair value. No significant receivable balances are impaired at the reporting end dates.

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 36px">10</td> <td>Advances from related parties</td></tr> </table> Non-current <table cellpadding="0" cellspacing="0" id="xdx_887_eifrs-full--DisclosureOfTransactionsBetweenRelatedPartiesExplanatory_pn3n3_zUqx6ZloYHOc" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Advances from related parties (Details)"> <tr style="vertical-align: bottom"> <td>Schedule of advances from related parties</td> <td> </td> <td colspan="2" id="xdx_491_20250101__20251231_z7z7l3V26616" style="text-align: center"> </td> <td> </td> <td> </td> <td colspan="2" id="xdx_490_20240101__20241231_zxO8ZB8csYaT" style="text-align: center"> </td> <td> </td> </tr> <tr> <td style="vertical-align: bottom; text-align: center"> </td> <td style="vertical-align: bottom"> </td> <td colspan="2" style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: center">2025</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td colspan="2" style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: center">2024</td> <td style="vertical-align: bottom"> </td> </tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td> <td> </td> <td colspan="2" style="text-align: center">€</td> <td> </td> <td> </td> <td colspan="2" style="text-align: center">€</td> <td> </td> </tr> <tr id="xdx_402_eifrs-full--BorrowingsAbstract_iB_zRCAFq0hEJ8J" style="vertical-align: bottom"> <td>Borrowings held at amortized cost:</td> <td> </td> <td colspan="2" style="text-align: center"> </td> <td> </td> <td> </td> <td colspan="2" style="text-align: center"> </td> <td> </td> </tr> <tr id="xdx_401_eifrs-full--CashAdvancesAndLoansFromRelatedParties_d0_zog9JUf7NlEV" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 66%">Advances from related parties</td> <td style="width: 2%"> </td> <td style="border-bottom: black 2.25pt double; width: 1%"> </td> <td style="border-bottom: black 2.25pt double; width: 13%; text-align: right">907,671</td> <td style="width: 1%"> </td> <td style="width: 2%"> </td> <td style="border-bottom: black 2.25pt double; width: 1%"> </td> <td style="border-bottom: black 2.25pt double; width: 13%; text-align: right">–</td> <td style="width: 1%"> </td> </tr> </table> During the year, Jack Kaye, the Company’s Chief Executive Officer, has paid on behalf of the Company costs totaling €0.9 million in 2025 (2024: €0.1 million) in order for the Company to meet its obligations. Management has classified these advances, which are paid directly to vendors, within operations due to the nature of the transaction and represent non cash advances to the Company, with limited amounts representing cash financing activities. These advances are non-interest bearing and repayable only if, and when, the Company is able to do so. On June 30, 2024, €4.6 million of advances payable to Jack Kaye were converted to ordinary shares at a conversion ratio of 1 ordinary share for the equivalent of every $10 owed. Other creditors also converted amounts owed to them to equity on the same ratio, leaving a balance of €39,755 in Trade and other payables on the Consolidated Statement of Financial Position as of December 31, 2024. Included in the balance is €30,804 owed to Jack Kaye. See Note 21 Related party transactions for additional information.

<table cellpadding="0" cellspacing="0" id="xdx_887_eifrs-full--DisclosureOfTransactionsBetweenRelatedPartiesExplanatory_pn3n3_zUqx6ZloYHOc" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Advances from related parties (Details)"> <tr style="vertical-align: bottom"> <td>Schedule of advances from related parties</td> <td> </td> <td colspan="2" id="xdx_491_20250101__20251231_z7z7l3V26616" style="text-align: center"> </td> <td> </td> <td> </td> <td colspan="2" id="xdx_490_20240101__20241231_zxO8ZB8csYaT" style="text-align: center"> </td> <td> </td> </tr> <tr> <td style="vertical-align: bottom; text-align: center"> </td> <td style="vertical-align: bottom"> </td> <td colspan="2" style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: center">2025</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td colspan="2" style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: center">2024</td> <td style="vertical-align: bottom"> </td> </tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td> <td> </td> <td colspan="2" style="text-align: center">€</td> <td> </td> <td> </td> <td colspan="2" style="text-align: center">€</td> <td> </td> </tr> <tr id="xdx_402_eifrs-full--BorrowingsAbstract_iB_zRCAFq0hEJ8J" style="vertical-align: bottom"> <td>Borrowings held at amortized cost:</td> <td> </td> <td colspan="2" style="text-align: center"> </td> <td> </td> <td> </td> <td colspan="2" style="text-align: center"> </td> <td> </td> </tr> <tr id="xdx_401_eifrs-full--CashAdvancesAndLoansFromRelatedParties_d0_zog9JUf7NlEV" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 66%">Advances from related parties</td> <td style="width: 2%"> </td> <td style="border-bottom: black 2.25pt double; width: 1%"> </td> <td style="border-bottom: black 2.25pt double; width: 13%; text-align: right">907,671</td> <td style="width: 1%"> </td> <td style="width: 2%"> </td> <td style="border-bottom: black 2.25pt double; width: 1%"> </td> <td style="border-bottom: black 2.25pt double; width: 13%; text-align: right">–</td> <td style="width: 1%"> </td> </tr> </table>

907671000

900000

100000

4600000

39755

30804

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 36px; text-align: justify">11</td> <td style="text-align: justify">Fair value of financial liabilities</td></tr> </table> The directors consider that the carrying amounts of financial liabilities carried at amortized cost in the consolidated financial statements approximate their fair values.

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 36px; text-align: justify">12</td> <td style="text-align: justify">Liquidity risk</td></tr> </table> Liquidity risk is the risk that arises when the maturity of assets and liabilities does not match. An unmatched position potentially enhances profitability, but can also increase the risk of losses. The Board of Directors has procedures with the object of minimizing such losses such as maintaining sufficient cash and other highly liquid current assets and by having the ability to receive advances from related parties and/or an adequate amount of committed credit facilities. The following table details the remaining contractual maturity for the Company’s financial liabilities with agreed repayment periods. The contractual maturity is based on the earliest date on which the Company may be required to pay. <table cellpadding="0" cellspacing="0" id="xdx_888_eifrs-full--DisclosureOfMaturityAnalysisForLiquidityRiskThatArisesFromContractsWithinScopeOfIFRS17Explanatory_zUqmtsxiQkp8" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Liquidity risk (Details)"> <tr style="vertical-align: bottom"> <td>Schedule of liquidity risk</td> <td> </td> <td colspan="2" style="text-align: center"> </td> <td> </td></tr> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">5+ years</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td colspan="2" style="text-align: center">€</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>At December 31, 2024</td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="width: 83%">Advances from related parties</td> <td style="width: 2%"> </td> <td style="border-bottom: black 2.25pt double; width: 1%"> </td> <td id="xdx_987_ecustom--MaturityAnalysisForDerivativeFinancialLiability_d0_c20240101__20241231__ifrs-full--MaturityAxis__custom--LaterThanFiveYearMember_z7Yo5OBNgs9k" style="border-bottom: black 2.25pt double; width: 13%; text-align: right" title="Advances from related parties">–</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>At December 31, 2025</td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Advances from related parties</td> <td> </td> <td style="border-bottom: black 2.25pt double"> </td> <td id="xdx_984_ecustom--MaturityAnalysisForDerivativeFinancialLiability_d0_c20250101__20251231__ifrs-full--MaturityAxis__custom--LaterThanFiveYearMember_zYtEhNC3vWaG" style="border-bottom: black 2.25pt double; text-align: right" title="Advances from related parties">–</td> <td> </td></tr> </table>

<table cellpadding="0" cellspacing="0" id="xdx_888_eifrs-full--DisclosureOfMaturityAnalysisForLiquidityRiskThatArisesFromContractsWithinScopeOfIFRS17Explanatory_zUqmtsxiQkp8" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Liquidity risk (Details)"> <tr style="vertical-align: bottom"> <td>Schedule of liquidity risk</td> <td> </td> <td colspan="2" style="text-align: center"> </td> <td> </td></tr> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">5+ years</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td colspan="2" style="text-align: center">€</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>At December 31, 2024</td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="width: 83%">Advances from related parties</td> <td style="width: 2%"> </td> <td style="border-bottom: black 2.25pt double; width: 1%"> </td> <td id="xdx_987_ecustom--MaturityAnalysisForDerivativeFinancialLiability_d0_c20240101__20241231__ifrs-full--MaturityAxis__custom--LaterThanFiveYearMember_z7Yo5OBNgs9k" style="border-bottom: black 2.25pt double; width: 13%; text-align: right" title="Advances from related parties">–</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>At December 31, 2025</td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Advances from related parties</td> <td> </td> <td style="border-bottom: black 2.25pt double"> </td> <td id="xdx_984_ecustom--MaturityAnalysisForDerivativeFinancialLiability_d0_c20250101__20251231__ifrs-full--MaturityAxis__custom--LaterThanFiveYearMember_zYtEhNC3vWaG" style="border-bottom: black 2.25pt double; text-align: right" title="Advances from related parties">–</td> <td> </td></tr> </table>

0 0

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 36px">13</td> <td>Market risk management</td></tr> </table> The geopolitical situation in Eastern Europe intensified on February 24, 2022, with the commencement of the conflict between Russia and Ukraine. As at the date of authorizing these consolidated financial statements for issue, the conflict continues to evolve as military activity proceeds. In addition to the impact of these events on entities that have operations in Russia, Ukraine, or Belarus or that conduct business with counterparties in those jurisdictions, the conflict has affected economies and financial markets globally and has exacerbated ongoing macroeconomic challenges. The European Union, as well as the United States of America, Switzerland, the United Kingdom and other countries, have imposed a series of restrictive measures (sanctions) against the Russian and Belarusian governments, various companies, and certain individuals. These sanctions include asset freezes and prohibitions from making funds available to sanctioned individuals and entities. In addition, travel bans applicable to sanctioned individuals prevent them from entering or transiting through the relevant territories. The Republic of Cyprus has adopted United Nations and European Union measures. The continuing evolution of the conflict may lead to the possibility of additional sanctions or other regulatory actions in the future. Emerging uncertainty regarding the global supply of commodities as a result of the conflict between Russia and Ukraine may also disrupt global trade flows and place upward pressure on commodity prices and input costs. Challenges for companies may include reduced availability of funding to ensure access to raw materials, increased financing costs, heightened counterparty risk and the potential for contractual non-performance. Geopolitical tensions in the Middle East have also intensified in recent years. The Israel-Gaza conflict escalated significantly after Hamas launched a major attack on Israel on October 7, 2023. More recently, during 2026, hostilities in the region have further expanded following military confrontations involving Iran, Israel and the United States. In February 2026, coordinated military strikes by Israel and the United States against targets in Iran led to retaliatory actions by Iran across the region, contributing to a broader regional security crisis and disruption to shipping routes and energy markets. These developments have increased uncertainty in global financial markets and may affect international trade, energy supply chains and global commodity prices. In particular, tensions affecting key maritime transit routes in the Middle East, including the Strait of Hormuz, have contributed to volatility in global oil and gas markets and heightened geopolitical risk for international commerce. Entities with material subsidiaries, operations, investments, contractual arrangements or joint ventures in the affected regions may be significantly exposed to operational disruptions, financial market volatility and supply chain interruptions. Entities that do not have direct exposure to the Middle East may nevertheless be affected by broader economic consequences, including increased volatility in global energy prices, foreign exchange markets and capital markets. The Company has no direct exposure to Russia, Ukraine or Belarus and does not maintain operations, investments, or counterparties in Israel, Gaza, Iran or other jurisdictions directly involved in the ongoing conflicts. Accordingly, the Company does not expect a significant impact arising from direct exposures to these countries. Despite the limited direct exposure, the conflicts may negatively impact the broader European and global economy. In particular, geopolitical instability may adversely affect the tourism and services industries in Cyprus. Furthermore, increasing energy prices, fluctuations in foreign exchange rates, volatility in financial markets, rising interest rates, supply chain disruptions and inflationary pressures may indirectly impact the operations of the Company. The indirect implications will depend on the extent and duration of these geopolitical developments and remain uncertain. Management has considered the unique circumstances and the risk exposures of the Company and has concluded that, as of the date of authorization of these consolidated financial statements, there has been no material impact on the Company’s financial position or results of operations. However, due to the evolving nature of these geopolitical events and the high degree of uncertainty surrounding their potential economic effects, management will continue to monitor developments closely and will assess the need for further action should the situation materially change.

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 36px">14</td> <td>Trade and other payables</td></tr> </table> <table cellpadding="0" cellspacing="0" id="xdx_88E_ecustom--ScheduleOfTradeAndOtherPayablesTableTextBlock_zw61br5oEwHb" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Trade and other payables (Details - Trade and other payables)"> <tr style="vertical-align: bottom"> <td>Schedule of trade and other payables</td> <td> </td> <td> </td> <td id="xdx_49E_20251231_zC9YpGzkgQ0u" style="text-align: center"> </td> <td> </td> <td> </td> <td> </td> <td id="xdx_495_20241231_z54hhsv9Dnsa" style="text-align: center"> </td> <td> </td> </tr> <tr> <td style="vertical-align: bottom; text-align: center"> </td> <td style="vertical-align: bottom"> </td> <td colspan="2" style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: center">2025</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td colspan="2" style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: center">2024</td> <td style="vertical-align: bottom"> </td> </tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td> <td> </td> <td colspan="2" style="text-align: center">€</td> <td> </td> <td> </td> <td colspan="2" style="text-align: center">€</td> <td> </td> </tr> <tr id="xdx_404_eifrs-full--TradeAndOtherPayablesToTradeSuppliers_iI_zqnHgwf2Tot9" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 66%">Trade payables</td> <td style="width: 2%"> </td> <td style="width: 1%"> </td> <td style="width: 13%; text-align: right">17,174</td> <td style="width: 1%"> </td> <td style="width: 2%"> </td> <td style="width: 1%"> </td> <td style="width: 13%; text-align: right">2,952</td> <td style="width: 1%"> </td> </tr> <tr id="xdx_407_eifrs-full--Accruals_iI_d0_z59mga5R2NaB" style="vertical-align: bottom; background-color: White"> <td>Accruals</td> <td> </td> <td> </td> <td style="text-align: right">71,337</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">6,000</td> <td> </td> </tr> <tr id="xdx_401_eifrs-full--OtherPayables_iI_d0_zjpzbWXOleGH" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Other payables</td> <td> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">–</td> <td> </td> <td> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">30,804</td> <td> </td> </tr> <tr id="xdx_40F_eifrs-full--TradeAndOtherPayables_iI_zi2pgdpW4VK8" style="vertical-align: bottom; background-color: White"> <td>Trade and other payables</td> <td> </td> <td style="border-bottom: black 2.25pt double"> </td> <td style="border-bottom: black 2.25pt double; text-align: right">88,511</td> <td> </td> <td> </td> <td style="border-bottom: black 2.25pt double"> </td> <td style="border-bottom: black 2.25pt double; text-align: right">39,756</td> <td> </td> </tr> </table> <table cellpadding="0" cellspacing="0" id="xdx_884_ecustom--AccrualRollforwardTableTextBlock_zxpIvrMKQX3W" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Trade and other payables (Details - Accruals)"> <tr style="vertical-align: bottom"> <td>Schedule of accrual rollforward</td> <td> </td> <td colspan="2" id="xdx_493_20250101__20251231_zLENWoIS9KIr" style="text-align: center"> </td> <td> </td> <td> </td> <td colspan="2" id="xdx_494_20240101__20241231_zZth9BgJJm6x" style="text-align: center"> </td> <td> </td></tr> <tr> <td style="vertical-align: bottom">Accruals</td> <td style="vertical-align: bottom"> </td> <td colspan="2" style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: center">2025</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td colspan="2" style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: center">2024</td> <td style="vertical-align: bottom"> </td> </tr> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td colspan="2" style="text-align: center">€</td> <td> </td> <td> </td> <td colspan="2" style="text-align: center">€</td> <td> </td> </tr> <tr id="xdx_400_eifrs-full--Accruals_iS_d0_zzPgivVY9gkf" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 66%">As of January 1,</td> <td style="width: 2%"> </td> <td style="width: 1%"> </td> <td style="width: 13%; text-align: right">6,000</td> <td style="width: 1%"> </td> <td style="width: 2%"> </td> <td style="width: 1%"> </td> <td style="width: 13%; text-align: right">–</td> <td style="width: 1%"> </td> </tr> <tr id="xdx_40E_ecustom--IncreaseInAccruals_zHRPhCWUfQYx" style="vertical-align: bottom; background-color: White"> <td>Additions</td> <td> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">65,337</td> <td> </td> <td> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">6,000</td> <td> </td> </tr> <tr id="xdx_40C_eifrs-full--Accruals_iE_zPaIZBfeHRcJ" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>As of December 31,</td> <td> </td> <td style="border-bottom: black 2.25pt double"> </td> <td style="border-bottom: black 2.25pt double; text-align: right">71,337</td> <td> </td> <td> </td> <td style="border-bottom: black 2.25pt double"> </td> <td style="border-bottom: black 2.25pt double; text-align: right">6,000</td> <td> </td> </tr> </table>

<table cellpadding="0" cellspacing="0" id="xdx_88E_ecustom--ScheduleOfTradeAndOtherPayablesTableTextBlock_zw61br5oEwHb" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Trade and other payables (Details - Trade and other payables)"> <tr style="vertical-align: bottom"> <td>Schedule of trade and other payables</td> <td> </td> <td> </td> <td id="xdx_49E_20251231_zC9YpGzkgQ0u" style="text-align: center"> </td> <td> </td> <td> </td> <td> </td> <td id="xdx_495_20241231_z54hhsv9Dnsa" style="text-align: center"> </td> <td> </td> </tr> <tr> <td style="vertical-align: bottom; text-align: center"> </td> <td style="vertical-align: bottom"> </td> <td colspan="2" style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: center">2025</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td colspan="2" style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: center">2024</td> <td style="vertical-align: bottom"> </td> </tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td> <td> </td> <td colspan="2" style="text-align: center">€</td> <td> </td> <td> </td> <td colspan="2" style="text-align: center">€</td> <td> </td> </tr> <tr id="xdx_404_eifrs-full--TradeAndOtherPayablesToTradeSuppliers_iI_zqnHgwf2Tot9" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 66%">Trade payables</td> <td style="width: 2%"> </td> <td style="width: 1%"> </td> <td style="width: 13%; text-align: right">17,174</td> <td style="width: 1%"> </td> <td style="width: 2%"> </td> <td style="width: 1%"> </td> <td style="width: 13%; text-align: right">2,952</td> <td style="width: 1%"> </td> </tr> <tr id="xdx_407_eifrs-full--Accruals_iI_d0_z59mga5R2NaB" style="vertical-align: bottom; background-color: White"> <td>Accruals</td> <td> </td> <td> </td> <td style="text-align: right">71,337</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">6,000</td> <td> </td> </tr> <tr id="xdx_401_eifrs-full--OtherPayables_iI_d0_zjpzbWXOleGH" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Other payables</td> <td> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">–</td> <td> </td> <td> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">30,804</td> <td> </td> </tr> <tr id="xdx_40F_eifrs-full--TradeAndOtherPayables_iI_zi2pgdpW4VK8" style="vertical-align: bottom; background-color: White"> <td>Trade and other payables</td> <td> </td> <td style="border-bottom: black 2.25pt double"> </td> <td style="border-bottom: black 2.25pt double; text-align: right">88,511</td> <td> </td> <td> </td> <td style="border-bottom: black 2.25pt double"> </td> <td style="border-bottom: black 2.25pt double; text-align: right">39,756</td> <td> </td> </tr> </table>

17174

2952

71337

6000

30804

88511

39756

<table cellpadding="0" cellspacing="0" id="xdx_884_ecustom--AccrualRollforwardTableTextBlock_zxpIvrMKQX3W" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Trade and other payables (Details - Accruals)"> <tr style="vertical-align: bottom"> <td>Schedule of accrual rollforward</td> <td> </td> <td colspan="2" id="xdx_493_20250101__20251231_zLENWoIS9KIr" style="text-align: center"> </td> <td> </td> <td> </td> <td colspan="2" id="xdx_494_20240101__20241231_zZth9BgJJm6x" style="text-align: center"> </td> <td> </td></tr> <tr> <td style="vertical-align: bottom">Accruals</td> <td style="vertical-align: bottom"> </td> <td colspan="2" style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: center">2025</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td colspan="2" style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: center">2024</td> <td style="vertical-align: bottom"> </td> </tr> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td colspan="2" style="text-align: center">€</td> <td> </td> <td> </td> <td colspan="2" style="text-align: center">€</td> <td> </td> </tr> <tr id="xdx_400_eifrs-full--Accruals_iS_d0_zzPgivVY9gkf" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 66%">As of January 1,</td> <td style="width: 2%"> </td> <td style="width: 1%"> </td> <td style="width: 13%; text-align: right">6,000</td> <td style="width: 1%"> </td> <td style="width: 2%"> </td> <td style="width: 1%"> </td> <td style="width: 13%; text-align: right">–</td> <td style="width: 1%"> </td> </tr> <tr id="xdx_40E_ecustom--IncreaseInAccruals_zHRPhCWUfQYx" style="vertical-align: bottom; background-color: White"> <td>Additions</td> <td> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">65,337</td> <td> </td> <td> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">6,000</td> <td> </td> </tr> <tr id="xdx_40C_eifrs-full--Accruals_iE_zPaIZBfeHRcJ" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>As of December 31,</td> <td> </td> <td style="border-bottom: black 2.25pt double"> </td> <td style="border-bottom: black 2.25pt double; text-align: right">71,337</td> <td> </td> <td> </td> <td style="border-bottom: black 2.25pt double"> </td> <td style="border-bottom: black 2.25pt double; text-align: right">6,000</td> <td> </td> </tr> </table>

6000

65337 6000

71337

6000

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 36px">15</td> <td>Share capital – as restated</td></tr> </table> <table cellpadding="0" cellspacing="0" id="xdx_88B_eifrs-full--DisclosureOfClassesOfShareCapitalExplanatory_zH5PV8bWjhlG" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Share capital (Details)"> <tr style="vertical-align: bottom"> <td>Schedule of share capital</td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="text-align: center; font-weight: bold"> </td> <td style="font-weight: bold; text-align: center"> </td><td style="font-weight: bold; text-align: center">Number</td><td style="font-weight: bold; text-align: center"> </td><td style="text-align: center; font-weight: bold"> </td> <td style="font-weight: bold; text-align: center"> </td><td style="font-weight: bold; text-align: center">Number</td><td style="font-weight: bold; text-align: center"> </td><td style="text-align: center; font-weight: bold"> </td> <td style="font-weight: bold; text-align: center"> </td><td style="font-weight: bold; text-align: center">€</td><td style="font-weight: bold; text-align: center"> </td><td style="text-align: center; font-weight: bold"> </td> <td style="font-weight: bold; text-align: center"> </td><td style="font-weight: bold; text-align: center">€</td><td style="font-weight: bold; text-align: center"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 32%; text-align: left; padding-bottom: 2.5pt">Ordinary share capital authorized Par value of €.01</td><td style="width: 2%; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left"> </td><td id="xdx_983_eifrs-full--NumberOfSharesAuthorised_iI_c20251231_zuSkhcU9ujdq" style="border-bottom: Black 2.5pt double; width: 13%; text-align: right" title="Number of shares authorised">100,000,000</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left"> </td><td id="xdx_98E_eifrs-full--NumberOfSharesAuthorised_iI_c20241231_zb5jJ8y1PMfp" style="border-bottom: Black 2.5pt double; width: 13%; text-align: right" title="Number of shares authorised">100,000,000</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left"> </td><td id="xdx_984_ecustom--NumberOfSharesAuthorisedEuro_iI_uShares_c20251231_zg3Q4bt6iQEI" style="border-bottom: Black 2.5pt double; width: 13%; text-align: right" title="Number of shares authorised euro">1,000,000</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left"> </td><td id="xdx_983_ecustom--NumberOfSharesAuthorisedEuro_iI_uShares_c20241231_zpPY9o2soAo5" style="border-bottom: Black 2.5pt double; width: 13%; text-align: right" title="Number of shares authorised euro">1,000,000</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: right"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Issued and fully paid Par value of €.01</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_988_eifrs-full--NumberOfSharesIssued_iI_c20251231_zmOqQoTbJyuQ" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of shares issued">25,000,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_986_eifrs-full--NumberOfSharesIssued_iI_c20241231_zUamR0SQZWNC" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of shares issued and fully paid">25,000,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98B_ecustom--NumberOfSharesIssuedEuro_iI_uShares_c20251231_zsxS7VZ0gk9z" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of shares issued">250,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98D_ecustom--NumberOfSharesIssuedEuro_iI_uShares_c20241231_znKkHuDXNiuD" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of shares issued and fully paid euro">250,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <table cellpadding="0" cellspacing="0" id="xdx_881_ecustom--DisclosureOfClassesOfShareCapitalExplanatory1_zuBrfcWP1IlK" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Share capital (Details - Shares rollforward)"> <tr style="vertical-align: bottom"> <td style="text-align: left">Schedule of shares issued and fully paid</td> <td> </td> <td colspan="2" id="xdx_493_20250101__20251231_zemBozz6IZM_z7yt2jPZ1boN" style="text-align: center"> </td> <td> </td> <td> </td> <td colspan="2" id="xdx_493_20240101__20241231_zI2iCy9vYls5" style="text-align: center"> </td> <td> </td> </tr> <tr style="vertical-align: bottom"> <td>Shares Issued and Fully Paid</td> <td> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">2025</td> <td> </td> <td> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">2024</td> <td> </td> </tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td> <td> </td> <td colspan="2"> </td> <td> </td> <td> </td> <td colspan="2"> </td> <td> </td> </tr> <tr id="xdx_40D_eifrs-full--NumberOfSharesIssued_iS_zfB0WafvW5LK" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 66%">As of January 1,</td> <td style="width: 2%"> </td> <td style="width: 1%"> </td> <td style="width: 13%; text-align: right">25,000,000</td> <td style="width: 1%"> </td> <td style="width: 2%"> </td> <td style="width: 1%"> </td> <td style="width: 13%; text-align: right">20,000,000</td> <td style="width: 1%"> </td> </tr> <tr id="xdx_408_eifrs-full--IncreaseDecreaseInNumberOfSharesOutstanding_d0_zvv041EKhKPT" style="vertical-align: bottom; background-color: White"> <td>Additions</td> <td> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">–</td> <td> </td> <td> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">5,000,000</td> <td> </td> </tr> <tr id="xdx_40A_eifrs-full--NumberOfSharesIssued_iE_zzfbqlhFM7Md" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>As of December 31,</td> <td> </td> <td style="border-bottom: black 2.25pt double"> </td> <td style="border-bottom: black 2.25pt double; text-align: right">25,000,000</td> <td> </td> <td> </td> <td style="border-bottom: black 2.25pt double"> </td> <td style="border-bottom: black 2.25pt double; text-align: right">25,000,000</td> <td> </td> </tr> </table> On November 29, 2022, the Company was formed with an initial issuance of 12,258,458 shares of stock at € .01 par value for a total of € 122,585. During 2023, the Company completed the February 2023 common-control transaction pursuant to which intellectual property was transferred from Davion Healthcare Limited (United Kingdom) to the Company. In connection with the overall transaction, the Company’s issued share capital was reorganised such that 12,258,458 ordinary shares were held by the relevant shareholders and an additional 7,741,542 ordinary shares were issued at €0.01 par value, resulting in 20,000,000 ordinary shares in issue. The intellectual property transferred in the transaction has been recognised separately at its predecessor carrying amount, as described in Note 7. During the year ended 2024, the Company issued 4,401,800 shares of stock to various creditors and shareholders in exchange of amounts due to them of €919,663 and issued 598,246 shares of stock to its officers in exchange for amounts due to them of €5,600,000. The Company is not subject to any externally imposed capital requirements.

<table cellpadding="0" cellspacing="0" id="xdx_88B_eifrs-full--DisclosureOfClassesOfShareCapitalExplanatory_zH5PV8bWjhlG" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Share capital (Details)"> <tr style="vertical-align: bottom"> <td>Schedule of share capital</td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="text-align: center; font-weight: bold"> </td> <td style="font-weight: bold; text-align: center"> </td><td style="font-weight: bold; text-align: center">Number</td><td style="font-weight: bold; text-align: center"> </td><td style="text-align: center; font-weight: bold"> </td> <td style="font-weight: bold; text-align: center"> </td><td style="font-weight: bold; text-align: center">Number</td><td style="font-weight: bold; text-align: center"> </td><td style="text-align: center; font-weight: bold"> </td> <td style="font-weight: bold; text-align: center"> </td><td style="font-weight: bold; text-align: center">€</td><td style="font-weight: bold; text-align: center"> </td><td style="text-align: center; font-weight: bold"> </td> <td style="font-weight: bold; text-align: center"> </td><td style="font-weight: bold; text-align: center">€</td><td style="font-weight: bold; text-align: center"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 32%; text-align: left; padding-bottom: 2.5pt">Ordinary share capital authorized Par value of €.01</td><td style="width: 2%; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left"> </td><td id="xdx_983_eifrs-full--NumberOfSharesAuthorised_iI_c20251231_zuSkhcU9ujdq" style="border-bottom: Black 2.5pt double; width: 13%; text-align: right" title="Number of shares authorised">100,000,000</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left"> </td><td id="xdx_98E_eifrs-full--NumberOfSharesAuthorised_iI_c20241231_zb5jJ8y1PMfp" style="border-bottom: Black 2.5pt double; width: 13%; text-align: right" title="Number of shares authorised">100,000,000</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left"> </td><td id="xdx_984_ecustom--NumberOfSharesAuthorisedEuro_iI_uShares_c20251231_zg3Q4bt6iQEI" style="border-bottom: Black 2.5pt double; width: 13%; text-align: right" title="Number of shares authorised euro">1,000,000</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left"> </td><td id="xdx_983_ecustom--NumberOfSharesAuthorisedEuro_iI_uShares_c20241231_zpPY9o2soAo5" style="border-bottom: Black 2.5pt double; width: 13%; text-align: right" title="Number of shares authorised euro">1,000,000</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: right"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Issued and fully paid Par value of €.01</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_988_eifrs-full--NumberOfSharesIssued_iI_c20251231_zmOqQoTbJyuQ" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of shares issued">25,000,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_986_eifrs-full--NumberOfSharesIssued_iI_c20241231_zUamR0SQZWNC" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of shares issued and fully paid">25,000,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98B_ecustom--NumberOfSharesIssuedEuro_iI_uShares_c20251231_zsxS7VZ0gk9z" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of shares issued">250,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98D_ecustom--NumberOfSharesIssuedEuro_iI_uShares_c20241231_znKkHuDXNiuD" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of shares issued and fully paid euro">250,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

100000000

1000000 1000000

25000000

250000 250000 <table cellpadding="0" cellspacing="0" id="xdx_881_ecustom--DisclosureOfClassesOfShareCapitalExplanatory1_zuBrfcWP1IlK" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Share capital (Details - Shares rollforward)"> <tr style="vertical-align: bottom"> <td style="text-align: left">Schedule of shares issued and fully paid</td> <td> </td> <td colspan="2" id="xdx_493_20250101__20251231_zemBozz6IZM_z7yt2jPZ1boN" style="text-align: center"> </td> <td> </td> <td> </td> <td colspan="2" id="xdx_493_20240101__20241231_zI2iCy9vYls5" style="text-align: center"> </td> <td> </td> </tr> <tr style="vertical-align: bottom"> <td>Shares Issued and Fully Paid</td> <td> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">2025</td> <td> </td> <td> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">2024</td> <td> </td> </tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td> <td> </td> <td colspan="2"> </td> <td> </td> <td> </td> <td colspan="2"> </td> <td> </td> </tr> <tr id="xdx_40D_eifrs-full--NumberOfSharesIssued_iS_zfB0WafvW5LK" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 66%">As of January 1,</td> <td style="width: 2%"> </td> <td style="width: 1%"> </td> <td style="width: 13%; text-align: right">25,000,000</td> <td style="width: 1%"> </td> <td style="width: 2%"> </td> <td style="width: 1%"> </td> <td style="width: 13%; text-align: right">20,000,000</td> <td style="width: 1%"> </td> </tr> <tr id="xdx_408_eifrs-full--IncreaseDecreaseInNumberOfSharesOutstanding_d0_zvv041EKhKPT" style="vertical-align: bottom; background-color: White"> <td>Additions</td> <td> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">–</td> <td> </td> <td> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">5,000,000</td> <td> </td> </tr> <tr id="xdx_40A_eifrs-full--NumberOfSharesIssued_iE_zzfbqlhFM7Md" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>As of December 31,</td> <td> </td> <td style="border-bottom: black 2.25pt double"> </td> <td style="border-bottom: black 2.25pt double; text-align: right">25,000,000</td> <td> </td> <td> </td> <td style="border-bottom: black 2.25pt double"> </td> <td style="border-bottom: black 2.25pt double; text-align: right">25,000,000</td> <td> </td> </tr> </table>

25000000

20000000

5000000

25000000

12258458

122585

12258458 7741542 4401800 919663 598246 5600000

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 36px">16</td> <td>Share premium account – as restated </td></tr> </table> <table cellpadding="0" cellspacing="0" id="xdx_88E_ecustom--ScheduleOfSharePremiumAccountTableTextBlock_zx6Aa5ic36eV" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Share premium account (Details)"> <tr style="vertical-align: bottom"> <td style="width: 66%">Schedule of share premium account</td> <td style="width: 2%"> </td> <td style="width: 1%"> </td> <td id="xdx_49C_20250101__20251231_zCIlOZ2WZSJX" style="width: 13%; text-align: center"> </td> <td style="width: 1%"> </td> <td style="width: 2%"> </td> <td style="width: 1%"> </td> <td id="xdx_490_20240101__20241231_z5N5IuMq1gPH" style="width: 13%; text-align: center"> </td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td> <td> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">2025</td> <td> </td> <td> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">2024</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td> <td> </td> <td colspan="2" style="text-align: center">€</td> <td> </td> <td> </td> <td colspan="2" style="text-align: center">€</td> <td> </td></tr> <tr id="xdx_405_eifrs-full--SharePremium_iS_z6ASbLNLY26o" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>As of January 1,</td> <td> </td> <td> </td> <td style="text-align: right">9,395,382</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">2,925,719</td> <td> </td></tr> <tr id="xdx_405_ecustom--SharePremiumAdditions_d0_zXiVyZXZqwGx" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1pt">Additions</td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: right">–</td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: right">6,469,663</td> <td style="padding-bottom: 1pt"> </td></tr> <tr id="xdx_40A_eifrs-full--SharePremium_iE_zpsQHV1WYVM_zdOQzD7XqbSB" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>As of December 31,</td> <td> </td> <td style="border-bottom: black 2.25pt double"> </td> <td style="border-bottom: black 2.25pt double; text-align: right">9,395,382</td> <td> </td> <td> </td> <td style="border-bottom: black 2.25pt double"> </td> <td style="border-bottom: black 2.25pt double; text-align: right">9,395,382</td> <td> </td></tr> </table> Direct listing of ordinary shares in the United States In August 2025, the Company filed a registration statement with the United States Securities & Exchange Commission to list its 25 million outstanding ordinary shares on Nasdaq’s Global Market, solely to permit its registered shareholders the ability to trade their shares in the United States. The registered shareholders may or may not, elect to sell their ordinary shares covered by the registration statement, as and to the extent they determine. The Company will receive no proceeds from the direct listing and the Company’s registration statement became effective on November 28, 2025. As such, the Company is subject to the reporting requirements under the Securities & Exchange Commission as a foreign private issue but is still awaiting clearance from Nasdaq to be listed. In 2025, the Company entered into an advisory agreement in connection with its proposed Nasdaq direct listing. Under the terms of the agreement, upon the successful completion of the listing, the advisor is entitled to receive 125,000 ordinary shares of the Company and a cash fee of $200,000 plus reimbursable expenses up to $100,000. The share issuance represents a potential equity-settled share-based payment within the scope of IFRS 2 – Share-based Payment. Because the issuance of shares is contingent upon the successful completion of the listing, the performance condition has not been satisfied as of December 31, 2025, and therefore no share-based payment expense has been recognized in the accompanying consolidated financial statements. The Company will measure the transaction at the fair value of the shares issued on the listing date when the listing occurs.

<table cellpadding="0" cellspacing="0" id="xdx_88E_ecustom--ScheduleOfSharePremiumAccountTableTextBlock_zx6Aa5ic36eV" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Share premium account (Details)"> <tr style="vertical-align: bottom"> <td style="width: 66%">Schedule of share premium account</td> <td style="width: 2%"> </td> <td style="width: 1%"> </td> <td id="xdx_49C_20250101__20251231_zCIlOZ2WZSJX" style="width: 13%; text-align: center"> </td> <td style="width: 1%"> </td> <td style="width: 2%"> </td> <td style="width: 1%"> </td> <td id="xdx_490_20240101__20241231_z5N5IuMq1gPH" style="width: 13%; text-align: center"> </td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td> <td> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">2025</td> <td> </td> <td> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">2024</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td> <td> </td> <td colspan="2" style="text-align: center">€</td> <td> </td> <td> </td> <td colspan="2" style="text-align: center">€</td> <td> </td></tr> <tr id="xdx_405_eifrs-full--SharePremium_iS_z6ASbLNLY26o" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>As of January 1,</td> <td> </td> <td> </td> <td style="text-align: right">9,395,382</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">2,925,719</td> <td> </td></tr> <tr id="xdx_405_ecustom--SharePremiumAdditions_d0_zXiVyZXZqwGx" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1pt">Additions</td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: right">–</td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: right">6,469,663</td> <td style="padding-bottom: 1pt"> </td></tr> <tr id="xdx_40A_eifrs-full--SharePremium_iE_zpsQHV1WYVM_zdOQzD7XqbSB" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>As of December 31,</td> <td> </td> <td style="border-bottom: black 2.25pt double"> </td> <td style="border-bottom: black 2.25pt double; text-align: right">9,395,382</td> <td> </td> <td> </td> <td style="border-bottom: black 2.25pt double"> </td> <td style="border-bottom: black 2.25pt double; text-align: right">9,395,382</td> <td> </td></tr> </table>

9395382

2925719

0 6469663

9395382

25000000

125000

200000

100000

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 36px">17</td> <td>Revenue</td></tr> </table> Licensing Arrangement with NeuRX Health Inc – Historical Agreement On October 8, 2025, Davion Healthcare Plc entered into a Global Manufacturing and Distribution Agreement with NeuRX Health Inc. (“NeuRX”), which granted NeuRX an exclusive worldwide licence to manufacture, market, distribute and sell the Company's BreastCheck product. The agreement was subsequently amended in December 2025. The following disclosure describes the contractual terms in existence as at December 31, 2025. No revenue was recognised under the agreement during the year ended December 31, 2025. License Consideration Total license consideration of $120 million consists of: <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"><tr style="vertical-align: top; text-align: justify"> <td style="width: 24px"></td><td style="width: 24px; text-align: left">·</td><td style="text-align: justify">$1 million payable upon commercial launch in July 2026</td> </tr> <tr style="vertical-align: top; text-align: justify"> <td></td><td style="text-align: left">·</td><td style="text-align: justify">$19 million payable in twelve monthly installments beginning July 2026</td> </tr> <tr style="vertical-align: top; text-align: justify"> <td></td><td style="text-align: left">·</td><td style="text-align: justify">$100 million payable in ten annual installments of $10 million each beginning January 2027.</td> </tr></table> The Company expects the $100 million portion to be settled through issuance of NeuRX equity securities with a value of $10 million per issuance. Royalty structure NeuRX will pay: <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"><tr style="vertical-align: top; text-align: justify"> <td style="width: 24px"></td><td style="width: 24px; text-align: left">·</td><td style="text-align: justify">$5 per BreastCheck unit manufactured</td> </tr> <tr style="vertical-align: top; text-align: justify"> <td></td><td style="text-align: left">·</td><td style="text-align: justify">minimum royalties of $10 million per Contract Year ($100 million over 10 years)</td> </tr> <tr style="vertical-align: top; text-align: justify"> <td></td><td style="text-align: left">·</td><td style="text-align: justify">50% of net revenue from follow-on tests purchased by returning customers.</td> </tr></table> Subsequent termination of NeuRX agreement Subsequent to December 31, 2025, the Company terminated the Global Manufacturing and Distribution Agreement with NeuRX. As a consequence, NeuRX no longer holds exclusive worldwide manufacturing or distribution rights in respect of BreastCheck and the Company does not expect to receive the future license fees, equity consideration or minimum royalties described above under the terminated agreement. Following termination, the Company has adopted a commercialization strategy under which it may manufacture and distribute BreastCheck directly, through other members of the Davion group, or through third-party manufacturers and distributors appointed on a regional or territory-specific basis. NeuRX may remain a non-exclusive distributor of BreastCheck in the United States subject to the terms of any separate distribution arrangement. The termination was a non-adjusting event after the reporting period as it arose from circumstances occurring after December 31, 2025. No amounts relating to future NeuRX license fees, equity consideration or royalties had been recognised as revenue or receivables at December 31, 2025. Accounting for Equity Consideration Under the terms of the agreement existing at December 31, 2025, the $<span id="xdx_906_ecustom--DeferredRevenueFromContract_iI_pn6n6_c20251231__ifrs-full--ProductsAndServicesAxis__custom--NeuRXMember__ifrs-full--TypesOfContractsAxis__custom--NeuRXSharesMember_zmk5rjwIjfFI" title="Deferred revenue">100 million component of license consideration was contemplated to be settled through NeuRX equity securities. Following subsequent termination of the agreement, the Company no longer expects to receive this consideration under the terminated arrangement. Contract Liabilities Cash and equity consideration received prior to revenue recognition are recorded as contract liabilities. These balances are recognized as revenue over the service period.

120000000

1000000

19000000

100000000

10000000

100000000

10000000

100000000

P10Y

0.50

100000000

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 36px">18</td> <td>Earnings Per Share</td></tr> </table> Earnings per share was €(0.05) and €(0.07), as restated, for the years ended December 31, 2025 and 2024, respectively, with average shares outstanding of 25,000,000 and 22,909,836, respectively for each period. There are 125,000 ordinary shares that are contingently issuable upon completion of the Company’s Nasdaq listing. As the listing had not occurred as of December 31, 2025, these shares have been excluded from the calculation of basic and diluted earnings per share in accordance with IAS 33. There were no dilutive shares outstanding during the years ended December 31, 2025 and 2024.

-0.05

-0.07

25000000

22909836

125000

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 36px">19</td> <td>Subsequent Events</td></tr> </table> Acquisition of Davion Healthcare Corporation On January 1, 2026, the Company acquired <span id="xdx_904_eifrs-full--PercentageOfVotingEquityInterestsAcquired_iI_pip0_dp_c20260102__ifrs-full--NonadjustingEventsAfterReportingPeriodAxis__custom--NonadjustingEventsAfterReportingPeriodMember_zZTbadwDwnDB">100% of the outstanding equity interests of Davion Healthcare Corporation, an entity wholly owned by the Company’s Chief Executive Officer, for nominal consideration of $1. Management evaluated the transaction against the definition of a business under IFRS 3, and determined that the acquired entity did not meet the definition of a business, as it did not include substantive processes capable of producing outputs. The acquired entity’s assets consisted solely of $<span id="xdx_902_eifrs-full--CashAndCashEquivalentsRecognisedAsOfAcquisitionDate_iI_uUSD_c20260102__ifrs-full--NonadjustingEventsAfterReportingPeriodAxis__custom--NonadjustingEventsAfterReportingPeriodMember_zlHCqZKt0BIU">445,000 of cash and its liabilities consisted of a $<span id="xdx_908_eifrs-full--AmountsReceivableRelatedPartyTransactions_iI_uUSD_c20260102__ifrs-full--NonadjustingEventsAfterReportingPeriodAxis__custom--NonadjustingEventsAfterReportingPeriodMember_zKINMNpfeCVS">445,000 related party advance to the CEO, payable on demand and is non-interest bearing, and therefore the nominal purchase price reflected the entity’s equity value. Because the acquired entity contained only financial assets and financial liabilities and no substantive operations, the transaction was accounted for as the acquisition of a group of assets and liabilities rather than a business. The assets acquired and liabilities assumed were recognized at their respective carrying amounts, which approximate fair value, and the related-party advance remained an obligation of the acquired entity following the acquisition. Although the acquired entity was wholly owned by the Company’s Chief Executive Officer, management concluded the entities were not under common control, as the Chief Executive Officer does not control the Company within the meaning of IFRS 10, but instead only is able to exercise significant influence through his voting control of <span id="xdx_908_eifrs-full--PercentageOfVotingEquityInterestsAcquired_iI_pip0_dp_c20260102__ifrs-full--NonadjustingEventsAfterReportingPeriodAxis__custom--NonadjustingEventsAfterReportingPeriodMember__ifrs-full--CounterpartiesAxis__custom--CEOMember_zOPlyZt3mhpA" title="Acquired equity interests">41% of the ordinary shares of Davion. The transaction therefore represents a related-party transaction under IAS 24. Financial advisory fee In February 2026, the Company entered into a financial advisory agreement that requires a <span id="xdx_902_eifrs-full--PercentageOfVotingEquityInterestsAcquired_iI_pip0_dp_c20260228__ifrs-full--NonadjustingEventsAfterReportingPeriodAxis__custom--NonadjustingEventsAfterReportingPeriodMember_zzW4dDkD5SM6" title="Acquired equity interests">6% fee on future capital raising transactions and the issuance of <span id="xdx_90D_eifrs-full--NumberOfSharesIssued_iI_c20260228__ifrs-full--NonadjustingEventsAfterReportingPeriodAxis__custom--NonadjustingEventsAfterReportingPeriodMember_zp0CV6sa9LBG" title="Number of ordinary shares issued">100,000 ordinary shares upon the Company being listing on any major U.S. exchange. <span id="xdx_907_eifrs-full--DescriptionOfAnyRetirementBenefitPlanTerminationTerms_c20260201__20260228__ifrs-full--NonadjustingEventsAfterReportingPeriodAxis__custom--NonadjustingEventsAfterReportingPeriodMember_zA713GYlOFuR" title="Termination, description">The agreement has a minimum term of 120 days plus a 12 month tail on termination. Secured Convertible note On March 10, 2026, the Company received $1,500,000 of cash related to the issuance of a $<span id="xdx_90D_eifrs-full--SecuredBankLoansReceived_iI_uUSD_c20260310__ifrs-full--NonadjustingEventsAfterReportingPeriodAxis__custom--NonadjustingEventsAfterReportingPeriodMember_z1wke9KQe7yb" title="Secured promissory note">1,655,000 secured promissory note (“the Note”) that matures six months from the date of issuance, at a <span id="xdx_908_ecustom--DebtInstrumentInterestRatesDuringPeriod_iI_dp_c20260310__ifrs-full--NonadjustingEventsAfterReportingPeriodAxis__custom--NonadjustingEventsAfterReportingPeriodMember_zLdYbiN5UbcC" title="Interest rate">9% interest rate. The Company has three options to extend the maturity date through June 2027 for an additional fee. The Note is convertible into ordinary shares at a fixed price of $12.36 per share at the holder’s option anytime. The Note may be prepaid at a premium of 115% of the outstanding balance subject to Company not being in default. The Company is required to paydown the Note with 20% of any fundraising proceeds up to the maximum amount outstanding. The Note is secured by a security interest in certain intellectual property. Additionally, the investor received 200,000 warrants subject to the following conditions: i) a term of 12 months from the effective date of the Company’s listing on Nasdaq, ii) at an exercise price of $13.00 and iii) exercisable for cash only. The Company is required to register ordinary shares sufficient to cover the full conversion of the Note at the fixed price plus the shares underlying the warrants or approximately 139,925 shares. Contingent Term Loan On March 24, 2026 the Company entered into an irrevocable committed term loan facility of up to $2.0 million for a one year period from the date of the Company being listed on Nasdaq (“the availability period”). During the availability period, at the Company’s discretion, it can make draws at a minimum of $250,000 tranches and repay such draws within 15 months, at a rate of 15%. Establishment of United Kingdom subsidiaries and proposed financing programme Subsequent to December 31, 2025, the Company established Davion Healthcare Ltd (UK) as a wholly owned subsidiary in the United Kingdom. Davion Healthcare Ltd (UK) subsequently established Davion Healthcare Finance Ltd as its wholly owned subsidiary for the purpose of supporting the Group's acquisition financing strategy. Davion Healthcare Finance Ltd is intended to act as issuer in connection with a proposed institutional corporate bond programme. As of the date these financial statements were authorised for issue, the bond programme had not commenced, no bonds had been issued and no proceeds had been raised.

445000

0.41

0.06

100000

The agreement has a minimum term of 120 days plus a 12 month tail on termination.

1500000

1655000

0.09 200000

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 36px">20</td> <td>Commitments & contingencies</td></tr> </table> Infrastructure, software license and development agreement The Company has developed and maintains a secure test portal and customer database intended to support the commercialization and use of its products. The portal may be used in connection with products manufactured or distributed directly by the Company or members of the Davion group and may also be made available to third-party manufacturers, licensees or distributors where required. In September 2025, the Company entered into an infrastructure, software and services agreement relating to development and operation of the test portal to support the commercialization of BreastCheck for $0.7 million, subject to annual renewals. Service fees after August 2026 will depend upon the nature and extent of services required to support the Company's ongoing commercialization activities. Direct listing advisory fees Upon the Company being listed on Nasdaq it is obligated to pay its direct listing advisor certain fees, including 125,000 ordinary shares at ~$12 per share (estimated listing price) and cash fees of $200,000 plus up to $100,000 of reimbursable expenses.

700000

125000

200000

100000

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 36px">21</td> <td>Related party transactions</td></tr> </table> Advances from related parties As the single largest shareholder, Jack Kaye our CEO, holds 41% of the ordinary shares of Company and is the sole provider of operational funding. At December 31, 2025, and 2024, Mr. Kaye was owed advances of €907,671 and €30,804, respectively, through companies that he controls, including Malbrite Limited, Rallinson Corporation and Davion Healthcare Corporation. The balance owed at December 31, 2024 is classified in Trade and other payables on the consolidated balance sheet. Mr. Kaye has pledged his financial support that is necessary for 12 months from the date of issuance of these consolidated financial statements. On June 30, 2024, advances to the Company by Jack Kaye amounting to €<span id="xdx_906_eifrs-full--AmountsPayableRelatedPartyTransactions_iI_pn5n6_c20240630__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--MrKayeMember_zZfpIBw7vmcK" title="Related party advances to company">4.6 million and €<span id="xdx_905_eifrs-full--AmountsPayableRelatedPartyTransactions_iI_pn6n6_c20240630__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--DavidPaulMember_zQ4X8MOzTWwq" title="Related party advances to company">1.0 million in fees due David Paul Alexander Over, a director of Davion Healthcare Plc, were converted into 598,246 shares at a conversion rate equivalent to one ordinary share for every $10 (Euro conversion equivalent to) owed. Remuneration of key management personnel In January 1st 2025, the Chief Executive Officer, Jack Kaye and the Chief Commercial Officer, David Paul Alexander (“the Executive Directors”), entered into service agreements with the Company in exchange for annual renumeration of €1,800,000 and €<span id="xdx_905_eifrs-full--EstimateOfContributionsExpectedToBePaidToPlan_c20250101__20251231__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--DavidPaulAlexanderMember_zDTXrAMBuNec" title="Annual renumeration">1,200,000, respectively including other executive level benefits. In March of 2025, the Executive Directors agreed to freeze their service contracts without any accrual being credited, until such time the Company is listed on a public exchange. In January 2026, these service agreements were cancelled with no fees owing through December 31, 2025. New service agreements will be put in place once the Company is listed on Nasdaq. The parties have agreed that new Service Agreements shall be established immediately prior to, or within fourteen days following, the listing of the Company’s securities on a regulated stock exchange. Such new agreement shall: reflect the current operational and financial position of the Company as a pre-revenue entity; and provide for compensation, benefits, and incentive arrangements commensurate with those typically applicable to executives of comparable small-capitalisation publicly listed companies. In December 2025 Andreas Ttofi, was appointed as the Company’s Chief Financial Officer and an Executive Director on the Board. Mr. Ttofi’s service agreement provides for a monthly salary of €10,000 plus other benefits, which will begin to accrue upon the Company being listed on Nasdaq. In January 2025 the Company added four additional independent directors and in December added one additional independent director to the Board of Directors. The independent directors have agreed to have their compensation frozen without any accrual being credited in 2025 and until such time that the Company is listed on a public exchange, at which time their renumeration will commence. For the year ended December 31, 2024, the Company incurred €400,000 with regards to director fees by David Paul Alexander Over, a director of Davion Healthcare Plc. and €600,000 with regards to service fees by Jack Kaye, a director of Davion Healthcare Plc.

0.41

907671

30804

P12M

4600000

1000000

598246

1800000

1200000

10000

400000

600000

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 36px"> 22</td> <td> Revision of historical accounting treatment – as restated</td></tr> </table> During the preparation of the consolidated financial statements for the year ended 31 December 2025, management identified an error in the historical accounting treatment applied to certain intellectual property assets. The February 2023 transfer of certain intellectual property assets had previously been accounted for in a manner that was not consistent with the company's accounting policies and the requirements of the applicable financial reporting framework. Upon completion of a detailed review, management concluded that the carrying amounts of the affected assets and the related expense recognition in prior periods had been misstated. Accordingly, the Company has corrected the error by retrospectively restating the previously issued financial information for the years ended 31 December 2023 and 31 December 2024, together with the opening balances as at 1 January 2025. The correction resulted in adjustments to intangible assets, accumulated amortization, share premium, deficit, operating loss and other related financial statement captions. The correction of the prior period error had no impact on the Company's revenues, cash flows, cash balances or operating activities for any period presented. The tables below present the effect of the restatement on the Company's previously reported consolidated statements of financial position, profit or loss and other comprehensive income, consolidated statements of changes in equity and cash flows for the periods presented. Effect on Statement of Financial Position At 31 December 2023 <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">As previously reported</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Adjustment</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Restated</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 49%; text-align: left">Intangible assets</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">€</td><td id="xdx_987_eifrs-full--IntangibleAssetsOtherThanGoodwill_iI_c20231231__srt--RestatementAxis__srt--ScenarioPreviouslyReportedMember_zEEDJv2nl9Uo" style="width: 13%; text-align: right" title="Intangible assets">65,000,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">€</td><td id="xdx_980_eifrs-full--IntangibleAssetsOtherThanGoodwill_iI_c20231231__srt--RestatementAxis__srt--RestatementAdjustmentMember_z727c4HHX6bi" style="width: 13%; text-align: right" title="Intangible assets">(62,205,721</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">€</td><td id="xdx_98D_eifrs-full--IntangibleAssetsOtherThanGoodwill_iI_c20231231_zwzguD6fBm9A" style="width: 13%; text-align: right" title="Intangible assets">2,794,279</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Share premium</td><td> </td> <td style="text-align: left">€</td><td id="xdx_98F_eifrs-full--SharePremium_iI_c20231231__srt--RestatementAxis__srt--ScenarioPreviouslyReportedMember_zTfydRxxm8tI" style="text-align: right">64,877,415</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">€</td><td id="xdx_98A_eifrs-full--SharePremium_iI_c20231231__srt--RestatementAxis__srt--RestatementAdjustmentMember_zS3uSZQ7N1fA" style="text-align: right">(61,951,696</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left">€</td><td id="xdx_980_eifrs-full--SharePremium_iI_c20231231_z6Kt6C81d0YF" style="text-align: right" title="Share premium">2,925,719</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Deficit</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_eifrs-full--RetainedEarnings_iI_c20231231__srt--RestatementAxis__srt--ScenarioPreviouslyReportedMember_zBpRmWOcTLbg" style="text-align: right">(5,308,332</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_eifrs-full--RetainedEarnings_iI_c20231231__srt--RestatementAxis__srt--RestatementAdjustmentMember_zrKREToKXepD" style="text-align: right">(254,025</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_eifrs-full--RetainedEarnings_iI_c20231231_zDuJV8FTldwg" style="text-align: right" title="Deficit">(5,562,357</td><td style="text-align: left">)</td></tr> </table> At 31 December 2024 <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">As previously reported</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Adjustment</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Restated</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 49%; text-align: left">Intangible Assets</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">€</td><td id="xdx_986_eifrs-full--IntangibleAssetsOtherThanGoodwill_iI_c20241231__srt--RestatementAxis__srt--ScenarioPreviouslyReportedMember_zauQ33gEhBe7" style="width: 13%; text-align: right" title="Intangible assets">65,000,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">€</td><td id="xdx_983_eifrs-full--IntangibleAssetsOtherThanGoodwill_iI_c20241231__srt--RestatementAxis__srt--RestatementAdjustmentMember_zKfaqlN6OZok" style="width: 13%; text-align: right" title="Intangible assets">(62,510,552</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">€</td><td id="xdx_983_eifrs-full--IntangibleAssetsOtherThanGoodwill_iI_c20241231_zfoxfTLho1ah" style="width: 13%; text-align: right" title="Intangible assets">2,489,448</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Share premium</td><td> </td> <td style="text-align: left">€</td><td id="xdx_981_eifrs-full--SharePremium_iI_c20241231__srt--RestatementAxis__srt--ScenarioPreviouslyReportedMember_zBdDwGqlIT3U" style="text-align: right">71,347,078</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">€</td><td id="xdx_980_eifrs-full--SharePremium_iI_c20241231__srt--RestatementAxis__srt--RestatementAdjustmentMember_zjeBVkJyyPhL" style="text-align: right">(61,951,696</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left">€</td><td id="xdx_98B_eifrs-full--SharePremium_iI_c20241231_zHIfbYBM4N27" style="text-align: right">9,395,382</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Deficit</td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_eifrs-full--RetainedEarnings_iI_c20241231__srt--RestatementAxis__srt--ScenarioPreviouslyReportedMember_z5Rd8A8vLHF7" style="text-align: right">(6,628,685</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_eifrs-full--RetainedEarnings_iI_c20241231__srt--RestatementAxis__srt--RestatementAdjustmentMember_z8e8JrctahuF" style="text-align: right">(558,856</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_eifrs-full--RetainedEarnings_iI_c20241231_zJdBC0VumPV5" style="text-align: right">(7,187,541</td><td style="text-align: left">)</td></tr> </table> At 31 December 2025 <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">As previously reported</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Adjustment</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Restated</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 49%; text-align: left">Intangible Assets</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">€</td><td id="xdx_982_eifrs-full--IntangibleAssetsOtherThanGoodwill_iI_c20251231__srt--RestatementAxis__srt--ScenarioPreviouslyReportedMember_zxExpsSwGsDo" style="width: 13%; text-align: right" title="Intangible assets">65,000,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">€</td><td id="xdx_986_eifrs-full--IntangibleAssetsOtherThanGoodwill_iI_c20251231__srt--RestatementAxis__srt--RestatementAdjustmentMember_z7NkgBWNgCqZ" style="width: 13%; text-align: right" title="Intangible assets">(62,815,382</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">€</td><td id="xdx_98A_eifrs-full--IntangibleAssetsOtherThanGoodwill_iI_c20251231_zXzC24SQikdC" style="width: 13%; text-align: right" title="Intangible assets">2,184,618</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Share premium</td><td> </td> <td style="text-align: left">€</td><td id="xdx_98D_eifrs-full--SharePremium_iI_c20251231__srt--RestatementAxis__srt--ScenarioPreviouslyReportedMember_zoyDbrDFEYgS" style="text-align: right">71,347,078</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">€</td><td id="xdx_98A_eifrs-full--SharePremium_iI_c20251231__srt--RestatementAxis__srt--RestatementAdjustmentMember_zZbG5brHrwIi" style="text-align: right">(61,951,696</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left">€</td><td id="xdx_982_eifrs-full--SharePremium_iI_c20251231_zAj1uhGyA1vD" style="text-align: right">9,395,382</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Deficit</td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_eifrs-full--RetainedEarnings_iI_c20251231__srt--RestatementAxis__srt--ScenarioPreviouslyReportedMember_zvIHPmw63Ne1" style="text-align: right">(7,452,662</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_eifrs-full--RetainedEarnings_iI_c20251231__srt--RestatementAxis__srt--RestatementAdjustmentMember_zxv2TO39XPb0" style="text-align: right">(863,686</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_eifrs-full--RetainedEarnings_iI_c20251231_z0MmhhVTmR2U" style="text-align: right">(8,316,348</td><td style="text-align: left">)</td></tr> </table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 36px">22</td> <td>Revision of historical accounting treatment – as restated (continued)</td></tr> </table> Effect on Statements of Cash Flows At 31 December 2023 <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">As previously reported</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Adjustment</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Restated</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center"> </td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center"> </td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center"> </td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 49%; text-align: left">Net loss</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">€</td><td id="xdx_989_eifrs-full--ProfitLoss_c20230101__20231231__srt--RestatementAxis__srt--ScenarioPreviouslyReportedMember_zKhddV1B5ws" style="width: 13%; text-align: right" title="Net loss">(5,308,332</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">€</td><td id="xdx_988_eifrs-full--ProfitLoss_c20230101__20231231__srt--RestatementAxis__srt--RestatementAdjustmentMember_z5c2knC45o12" style="width: 13%; text-align: right" title="Net loss">(254,025</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">€</td><td id="xdx_980_eifrs-full--ProfitLoss_c20230101__20231231_z8RblQ6rrY59" style="width: 13%; text-align: right" title="Net loss">(5,562,357</td><td style="width: 1%; text-align: left">)</td></tr> </table> At 31 December 2024 <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">As previously reported</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Adjustment</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Restated</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center"> </td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center"> </td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center"> </td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 49%; text-align: left">Net loss</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">€</td><td id="xdx_981_eifrs-full--ProfitLoss_c20240101__20241231__srt--RestatementAxis__srt--ScenarioPreviouslyReportedMember_zDWESYmLDt2g" style="width: 13%; text-align: right" title="Net loss">(1,320,353</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">€</td><td id="xdx_98B_eifrs-full--ProfitLoss_c20240101__20241231__srt--RestatementAxis__srt--RestatementAdjustmentMember_z43Dthr1LApl" style="width: 13%; text-align: right" title="Net loss">(304,830</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">€</td><td id="xdx_98C_eifrs-full--ProfitLoss_c20240101__20241231_znfPzY1QEkWj" style="width: 13%; text-align: right" title="Net loss">(1,625,183</td><td style="width: 1%; text-align: left">)</td></tr> </table> At 31 December 2025 <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">As previously reported</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Adjustment</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Restated</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center"> </td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center"> </td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center"> </td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 49%; text-align: left">Net loss</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">€</td><td id="xdx_98A_eifrs-full--ProfitLoss_c20250101__20251231__srt--RestatementAxis__srt--ScenarioPreviouslyReportedMember_zuJI2RorR1ug" style="width: 13%; text-align: right" title="Net loss">(823,977</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">€</td><td id="xdx_981_eifrs-full--ProfitLoss_c20250101__20251231__srt--RestatementAxis__srt--RestatementAdjustmentMember_zKXaUHUuWwef" style="width: 13%; text-align: right" title="Net loss">(304,830</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">€</td><td id="xdx_983_eifrs-full--ProfitLoss_c20250101__20251231_zjZV81rWM24f" style="width: 13%; text-align: right" title="Net loss">(1,128,807</td><td style="width: 1%; text-align: left">)</td></tr> </table> Reconciliation of Intangible Asset Balance <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 49%; text-align: left">Carrying value previously reported</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">€</td><td id="xdx_983_eifrs-full--IntangibleAssetsOtherThanGoodwill_iI_c20231231__srt--RestatementAxis__srt--ScenarioPreviouslyReportedMember_zFRLCBjgW6hb" style="width: 13%; text-align: right">65,000,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">€</td><td id="xdx_98B_eifrs-full--IntangibleAssetsOtherThanGoodwill_iI_c20241231__srt--RestatementAxis__srt--ScenarioPreviouslyReportedMember_zYI6oQzOd9c7" style="width: 13%; text-align: right">65,000,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">€</td><td id="xdx_988_eifrs-full--IntangibleAssetsOtherThanGoodwill_iI_c20251231__srt--RestatementAxis__srt--ScenarioPreviouslyReportedMember_zg95McVxq5ag" style="width: 13%; text-align: right">65,000,000</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Carrying value adjustment</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_eifrs-full--SharePremium_iI_c20231231__srt--RestatementAxis__srt--RestatementAdjustmentMember_zgLHG9cT01r2" style="text-align: right">(61,951,696</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eifrs-full--SharePremium_iI_c20241231__srt--RestatementAxis__srt--RestatementAdjustmentMember_zXygYTYYypt5" style="text-align: right">(61,951,696</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_eifrs-full--SharePremium_iI_c20251231__srt--RestatementAxis__srt--RestatementAdjustmentMember_zqi76j6aEYBf" style="text-align: right">(61,951,696</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Cumulative amortization adjustment</td><td> </td> <td style="text-align: left">€</td><td id="xdx_98C_ecustom--IntangibleAssetsAccumulatedAmortization_iNI_di_c20231231_zYJKFrwsPf6" style="text-align: right" title="Accumulated amortization">(254,025</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left">€</td><td id="xdx_986_ecustom--IntangibleAssetsAccumulatedAmortization_iNI_di_c20241231_zVoxFUyUmK7h" style="text-align: right" title="Accumulated amortization">(558,856</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left">€</td><td id="xdx_988_ecustom--IntangibleAssetsAccumulatedAmortization_iNI_di_c20251231_z28TvbEzGx7" style="text-align: right" title="Accumulated amortization">(863,686</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Restated carrying value</td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_eifrs-full--IntangibleAssetsOtherThanGoodwill_iI_c20231231_zQJXiydn1Wid" style="text-align: right">2,794,279</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_eifrs-full--IntangibleAssetsOtherThanGoodwill_iI_c20241231_z0dtoakVqDgi" style="text-align: right">2,489,448</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eifrs-full--IntangibleAssetsOtherThanGoodwill_iI_c20251231_zOaLihjX9uR8" style="text-align: right">2,184,618</td><td style="text-align: left"> </td></tr> </table> Effect on Profit or Loss At 31 December 2023 <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">As previously reported</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Adjustment</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Restated</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 49%; text-align: left">Amortization expense</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">€</td><td id="xdx_981_eifrs-full--Amortisation_d0_c20230101__20231231__srt--RestatementAxis__srt--ScenarioPreviouslyReportedMember_zOywb1Mdsqy" style="width: 13%; text-align: right" title="Amortization">–</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">€</td><td id="xdx_98B_eifrs-full--Amortisation_iN_di_c20230101__20231231__srt--RestatementAxis__srt--RestatementAdjustmentMember_zSwYvmNcGnc2" style="width: 13%; text-align: right" title="Amortization">(254,025</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">€</td><td id="xdx_988_eifrs-full--Amortisation_iN_di_c20230101__20231231_zPAl8GAoQqf2" style="width: 13%; text-align: right" title="Amortization">(254,025</td><td style="width: 1%; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Net loss</td><td> </td> <td style="text-align: left">€</td><td id="xdx_983_eifrs-full--ProfitLossFromOperatingActivities_c20230101__20231231__srt--RestatementAxis__srt--ScenarioPreviouslyReportedMember_zmq0CZ14jeaj" style="text-align: right" title="Operating loss">(5,308,332</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left">€</td><td id="xdx_983_eifrs-full--ProfitLossFromOperatingActivities_c20230101__20231231__srt--RestatementAxis__srt--RestatementAdjustmentMember_znyxtqdv26jk" style="text-align: right" title="Operating loss">(254,025</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left">€</td><td id="xdx_987_eifrs-full--ProfitLossFromOperatingActivities_c20230101__20231231_zOxTpp0NWMEg" style="text-align: right" title="Operating loss">(5,562,357</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Net loss per common share: Basic and diluted</td> <td> </td> <td>€</td> <td style="text-align: right">(0.35</td> <td>) </td> <td> </td> <td>€</td> <td style="text-align: right">(0.01</td> <td>) </td> <td> </td> <td>€</td> <td style="text-align: right">(0.36</td> <td>)</td></tr> </table> At 31 December 2024 <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">As previously reported</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Adjustment</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Restated</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 49%; text-align: left">Amortization expense</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">€</td><td id="xdx_988_eifrs-full--Amortisation_d0_c20240101__20241231__srt--RestatementAxis__srt--ScenarioPreviouslyReportedMember_zS5DTbwmnrMl" style="width: 13%; text-align: right" title="Amortization">–</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">€</td><td id="xdx_980_eifrs-full--Amortisation_iN_di_c20240101__20241231__srt--RestatementAxis__srt--RestatementAdjustmentMember_zYojpeuiLeBh" style="width: 13%; text-align: right" title="Amortization">(304,830</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">€</td><td id="xdx_98F_eifrs-full--Amortisation_iN_di_c20240101__20241231_zDDsUVTJkx4h" style="width: 13%; text-align: right" title="Amortization">(304,830</td><td style="width: 1%; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left"> Net loss</td><td> </td> <td style="text-align: left">€</td><td id="xdx_98A_eifrs-full--ProfitLossFromOperatingActivities_c20240101__20241231__srt--RestatementAxis__srt--ScenarioPreviouslyReportedMember_z55uaBrV9BNa" style="text-align: right" title="Operating loss">(1,320,353</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left">€</td><td id="xdx_982_eifrs-full--ProfitLossFromOperatingActivities_c20240101__20241231__srt--RestatementAxis__srt--RestatementAdjustmentMember_zNyaDQAwfKdj" style="text-align: right" title="Operating loss">(304,830</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left">€</td><td id="xdx_980_eifrs-full--ProfitLossFromOperatingActivities_c20240101__20241231_zt9MkCQHtn8k" style="text-align: right" title="Operating loss">(1,625,183</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Net loss per common share: Basic and diluted</td> <td> </td> <td>€</td> <td style="text-align: right">(0.06)</td> <td> </td> <td> </td> <td>€</td> <td style="text-align: right">(0.01</td> <td>) </td> <td> </td> <td>€</td> <td style="text-align: right">(0.07</td> <td>)</td></tr> </table> At 31 December 2025 <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">As previously reported</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Adjustment</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Restated</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 49%; text-align: left">Amortization expense</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">€</td><td id="xdx_981_eifrs-full--Amortisation_d0_c20250101__20251231__srt--RestatementAxis__srt--ScenarioPreviouslyReportedMember_zzORCmQSttJd" style="width: 13%; text-align: right" title="Amortization">–</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">€</td><td id="xdx_989_eifrs-full--Amortisation_iN_di0_c20250101__20251231__srt--RestatementAxis__srt--RestatementAdjustmentMember_z50yqjQCBAO5" style="width: 13%; text-align: right" title="Amortization">(304,830</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">€</td><td id="xdx_98F_eifrs-full--Amortisation_iN_di_c20250101__20251231_zi8vXMziGKz8" style="width: 13%; text-align: right" title="Amortization">(304,830</td><td style="width: 1%; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Net loss</td><td> </td> <td style="text-align: left">€</td><td id="xdx_989_eifrs-full--ProfitLossFromOperatingActivities_c20250101__20251231__srt--RestatementAxis__srt--ScenarioPreviouslyReportedMember_zdqwMIQq4LC5" style="text-align: right" title="Operating loss">(823,977</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left">€</td><td id="xdx_98F_eifrs-full--ProfitLossFromOperatingActivities_c20250101__20251231__srt--RestatementAxis__srt--RestatementAdjustmentMember_zLqQ2CGSsycg" style="text-align: right" title="Operating loss">(304,830</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left">€</td><td id="xdx_984_eifrs-full--ProfitLossFromOperatingActivities_c20250101__20251231_zi7hegW4ior3" style="text-align: right" title="Operating loss">(1,128,807</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Net loss per common share: Basic and diluted</td> <td> </td> <td>€</td> <td style="text-align: right">(0.03)</td> <td> </td> <td> </td> <td style="width: 1%">€</td> <td style="width: 13%; text-align: right">(0.02</td> <td>) </td> <td> </td> <td>€</td> <td style="text-align: right">(0.05</td> <td>)</td></tr> </table>

Effect on Statement of Financial Position At 31 December 2023 <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">As previously reported</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Adjustment</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Restated</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 49%; text-align: left">Intangible assets</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">€</td><td id="xdx_987_eifrs-full--IntangibleAssetsOtherThanGoodwill_iI_c20231231__srt--RestatementAxis__srt--ScenarioPreviouslyReportedMember_zEEDJv2nl9Uo" style="width: 13%; text-align: right" title="Intangible assets">65,000,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">€</td><td id="xdx_980_eifrs-full--IntangibleAssetsOtherThanGoodwill_iI_c20231231__srt--RestatementAxis__srt--RestatementAdjustmentMember_z727c4HHX6bi" style="width: 13%; text-align: right" title="Intangible assets">(62,205,721</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">€</td><td id="xdx_98D_eifrs-full--IntangibleAssetsOtherThanGoodwill_iI_c20231231_zwzguD6fBm9A" style="width: 13%; text-align: right" title="Intangible assets">2,794,279</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Share premium</td><td> </td> <td style="text-align: left">€</td><td id="xdx_98F_eifrs-full--SharePremium_iI_c20231231__srt--RestatementAxis__srt--ScenarioPreviouslyReportedMember_zTfydRxxm8tI" style="text-align: right">64,877,415</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">€</td><td id="xdx_98A_eifrs-full--SharePremium_iI_c20231231__srt--RestatementAxis__srt--RestatementAdjustmentMember_zS3uSZQ7N1fA" style="text-align: right">(61,951,696</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left">€</td><td id="xdx_980_eifrs-full--SharePremium_iI_c20231231_z6Kt6C81d0YF" style="text-align: right" title="Share premium">2,925,719</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Deficit</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_eifrs-full--RetainedEarnings_iI_c20231231__srt--RestatementAxis__srt--ScenarioPreviouslyReportedMember_zBpRmWOcTLbg" style="text-align: right">(5,308,332</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_eifrs-full--RetainedEarnings_iI_c20231231__srt--RestatementAxis__srt--RestatementAdjustmentMember_zrKREToKXepD" style="text-align: right">(254,025</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_eifrs-full--RetainedEarnings_iI_c20231231_zDuJV8FTldwg" style="text-align: right" title="Deficit">(5,562,357</td><td style="text-align: left">)</td></tr> </table> At 31 December 2024 <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">As previously reported</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Adjustment</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Restated</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 49%; text-align: left">Intangible Assets</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">€</td><td id="xdx_986_eifrs-full--IntangibleAssetsOtherThanGoodwill_iI_c20241231__srt--RestatementAxis__srt--ScenarioPreviouslyReportedMember_zauQ33gEhBe7" style="width: 13%; text-align: right" title="Intangible assets">65,000,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">€</td><td id="xdx_983_eifrs-full--IntangibleAssetsOtherThanGoodwill_iI_c20241231__srt--RestatementAxis__srt--RestatementAdjustmentMember_zKfaqlN6OZok" style="width: 13%; text-align: right" title="Intangible assets">(62,510,552</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">€</td><td id="xdx_983_eifrs-full--IntangibleAssetsOtherThanGoodwill_iI_c20241231_zfoxfTLho1ah" style="width: 13%; text-align: right" title="Intangible assets">2,489,448</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Share premium</td><td> </td> <td style="text-align: left">€</td><td id="xdx_981_eifrs-full--SharePremium_iI_c20241231__srt--RestatementAxis__srt--ScenarioPreviouslyReportedMember_zBdDwGqlIT3U" style="text-align: right">71,347,078</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">€</td><td id="xdx_980_eifrs-full--SharePremium_iI_c20241231__srt--RestatementAxis__srt--RestatementAdjustmentMember_zjeBVkJyyPhL" style="text-align: right">(61,951,696</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left">€</td><td id="xdx_98B_eifrs-full--SharePremium_iI_c20241231_zHIfbYBM4N27" style="text-align: right">9,395,382</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Deficit</td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_eifrs-full--RetainedEarnings_iI_c20241231__srt--RestatementAxis__srt--ScenarioPreviouslyReportedMember_z5Rd8A8vLHF7" style="text-align: right">(6,628,685</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_eifrs-full--RetainedEarnings_iI_c20241231__srt--RestatementAxis__srt--RestatementAdjustmentMember_z8e8JrctahuF" style="text-align: right">(558,856</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_eifrs-full--RetainedEarnings_iI_c20241231_zJdBC0VumPV5" style="text-align: right">(7,187,541</td><td style="text-align: left">)</td></tr> </table> At 31 December 2025 <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">As previously reported</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Adjustment</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Restated</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 49%; text-align: left">Intangible Assets</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">€</td><td id="xdx_982_eifrs-full--IntangibleAssetsOtherThanGoodwill_iI_c20251231__srt--RestatementAxis__srt--ScenarioPreviouslyReportedMember_zxExpsSwGsDo" style="width: 13%; text-align: right" title="Intangible assets">65,000,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">€</td><td id="xdx_986_eifrs-full--IntangibleAssetsOtherThanGoodwill_iI_c20251231__srt--RestatementAxis__srt--RestatementAdjustmentMember_z7NkgBWNgCqZ" style="width: 13%; text-align: right" title="Intangible assets">(62,815,382</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">€</td><td id="xdx_98A_eifrs-full--IntangibleAssetsOtherThanGoodwill_iI_c20251231_zXzC24SQikdC" style="width: 13%; text-align: right" title="Intangible assets">2,184,618</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Share premium</td><td> </td> <td style="text-align: left">€</td><td id="xdx_98D_eifrs-full--SharePremium_iI_c20251231__srt--RestatementAxis__srt--ScenarioPreviouslyReportedMember_zoyDbrDFEYgS" style="text-align: right">71,347,078</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">€</td><td id="xdx_98A_eifrs-full--SharePremium_iI_c20251231__srt--RestatementAxis__srt--RestatementAdjustmentMember_zZbG5brHrwIi" style="text-align: right">(61,951,696</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left">€</td><td id="xdx_982_eifrs-full--SharePremium_iI_c20251231_zAj1uhGyA1vD" style="text-align: right">9,395,382</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Deficit</td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_eifrs-full--RetainedEarnings_iI_c20251231__srt--RestatementAxis__srt--ScenarioPreviouslyReportedMember_zvIHPmw63Ne1" style="text-align: right">(7,452,662</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_eifrs-full--RetainedEarnings_iI_c20251231__srt--RestatementAxis__srt--RestatementAdjustmentMember_zxv2TO39XPb0" style="text-align: right">(863,686</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_eifrs-full--RetainedEarnings_iI_c20251231_z0MmhhVTmR2U" style="text-align: right">(8,316,348</td><td style="text-align: left">)</td></tr> </table>

65000000

-62205721

2794279

64877415

-61951696

2925719

-5308332

-254025

-5562357

65000000

-62510552

2489448

71347078

-61951696

9395382

-6628685

-558856

-7187541

65000000

-62815382

2184618

71347078

-61951696

9395382

-7452662

-863686

-8316348

Effect on Statements of Cash Flows At 31 December 2023 <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">As previously reported</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Adjustment</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Restated</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center"> </td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center"> </td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center"> </td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 49%; text-align: left">Net loss</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">€</td><td id="xdx_989_eifrs-full--ProfitLoss_c20230101__20231231__srt--RestatementAxis__srt--ScenarioPreviouslyReportedMember_zKhddV1B5ws" style="width: 13%; text-align: right" title="Net loss">(5,308,332</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">€</td><td id="xdx_988_eifrs-full--ProfitLoss_c20230101__20231231__srt--RestatementAxis__srt--RestatementAdjustmentMember_z5c2knC45o12" style="width: 13%; text-align: right" title="Net loss">(254,025</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">€</td><td id="xdx_980_eifrs-full--ProfitLoss_c20230101__20231231_z8RblQ6rrY59" style="width: 13%; text-align: right" title="Net loss">(5,562,357</td><td style="width: 1%; text-align: left">)</td></tr> </table> At 31 December 2024 <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">As previously reported</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Adjustment</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Restated</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center"> </td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center"> </td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center"> </td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 49%; text-align: left">Net loss</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">€</td><td id="xdx_981_eifrs-full--ProfitLoss_c20240101__20241231__srt--RestatementAxis__srt--ScenarioPreviouslyReportedMember_zDWESYmLDt2g" style="width: 13%; text-align: right" title="Net loss">(1,320,353</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">€</td><td id="xdx_98B_eifrs-full--ProfitLoss_c20240101__20241231__srt--RestatementAxis__srt--RestatementAdjustmentMember_z43Dthr1LApl" style="width: 13%; text-align: right" title="Net loss">(304,830</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">€</td><td id="xdx_98C_eifrs-full--ProfitLoss_c20240101__20241231_znfPzY1QEkWj" style="width: 13%; text-align: right" title="Net loss">(1,625,183</td><td style="width: 1%; text-align: left">)</td></tr> </table> At 31 December 2025 <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">As previously reported</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Adjustment</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Restated</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center"> </td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center"> </td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center"> </td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 49%; text-align: left">Net loss</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">€</td><td id="xdx_98A_eifrs-full--ProfitLoss_c20250101__20251231__srt--RestatementAxis__srt--ScenarioPreviouslyReportedMember_zuJI2RorR1ug" style="width: 13%; text-align: right" title="Net loss">(823,977</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">€</td><td id="xdx_981_eifrs-full--ProfitLoss_c20250101__20251231__srt--RestatementAxis__srt--RestatementAdjustmentMember_zKXaUHUuWwef" style="width: 13%; text-align: right" title="Net loss">(304,830</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">€</td><td id="xdx_983_eifrs-full--ProfitLoss_c20250101__20251231_zjZV81rWM24f" style="width: 13%; text-align: right" title="Net loss">(1,128,807</td><td style="width: 1%; text-align: left">)</td></tr> </table>

-5308332

-254025

-5562357

-1320353

-304830

-1625183

-823977

-304830

-1128807

Reconciliation of Intangible Asset Balance <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 49%; text-align: left">Carrying value previously reported</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">€</td><td id="xdx_983_eifrs-full--IntangibleAssetsOtherThanGoodwill_iI_c20231231__srt--RestatementAxis__srt--ScenarioPreviouslyReportedMember_zFRLCBjgW6hb" style="width: 13%; text-align: right">65,000,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">€</td><td id="xdx_98B_eifrs-full--IntangibleAssetsOtherThanGoodwill_iI_c20241231__srt--RestatementAxis__srt--ScenarioPreviouslyReportedMember_zYI6oQzOd9c7" style="width: 13%; text-align: right">65,000,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">€</td><td id="xdx_988_eifrs-full--IntangibleAssetsOtherThanGoodwill_iI_c20251231__srt--RestatementAxis__srt--ScenarioPreviouslyReportedMember_zg95McVxq5ag" style="width: 13%; text-align: right">65,000,000</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Carrying value adjustment</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_eifrs-full--SharePremium_iI_c20231231__srt--RestatementAxis__srt--RestatementAdjustmentMember_zgLHG9cT01r2" style="text-align: right">(61,951,696</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eifrs-full--SharePremium_iI_c20241231__srt--RestatementAxis__srt--RestatementAdjustmentMember_zXygYTYYypt5" style="text-align: right">(61,951,696</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_eifrs-full--SharePremium_iI_c20251231__srt--RestatementAxis__srt--RestatementAdjustmentMember_zqi76j6aEYBf" style="text-align: right">(61,951,696</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Cumulative amortization adjustment</td><td> </td> <td style="text-align: left">€</td><td id="xdx_98C_ecustom--IntangibleAssetsAccumulatedAmortization_iNI_di_c20231231_zYJKFrwsPf6" style="text-align: right" title="Accumulated amortization">(254,025</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left">€</td><td id="xdx_986_ecustom--IntangibleAssetsAccumulatedAmortization_iNI_di_c20241231_zVoxFUyUmK7h" style="text-align: right" title="Accumulated amortization">(558,856</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left">€</td><td id="xdx_988_ecustom--IntangibleAssetsAccumulatedAmortization_iNI_di_c20251231_z28TvbEzGx7" style="text-align: right" title="Accumulated amortization">(863,686</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Restated carrying value</td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_eifrs-full--IntangibleAssetsOtherThanGoodwill_iI_c20231231_zQJXiydn1Wid" style="text-align: right">2,794,279</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_eifrs-full--IntangibleAssetsOtherThanGoodwill_iI_c20241231_z0dtoakVqDgi" style="text-align: right">2,489,448</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eifrs-full--IntangibleAssetsOtherThanGoodwill_iI_c20251231_zOaLihjX9uR8" style="text-align: right">2,184,618</td><td style="text-align: left"> </td></tr> </table>

65000000

-61951696

254025 558856 863686

2794279

2489448

2184618

Effect on Profit or Loss At 31 December 2023 <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">As previously reported</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Adjustment</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Restated</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 49%; text-align: left">Amortization expense</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">€</td><td id="xdx_981_eifrs-full--Amortisation_d0_c20230101__20231231__srt--RestatementAxis__srt--ScenarioPreviouslyReportedMember_zOywb1Mdsqy" style="width: 13%; text-align: right" title="Amortization">–</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">€</td><td id="xdx_98B_eifrs-full--Amortisation_iN_di_c20230101__20231231__srt--RestatementAxis__srt--RestatementAdjustmentMember_zSwYvmNcGnc2" style="width: 13%; text-align: right" title="Amortization">(254,025</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">€</td><td id="xdx_988_eifrs-full--Amortisation_iN_di_c20230101__20231231_zPAl8GAoQqf2" style="width: 13%; text-align: right" title="Amortization">(254,025</td><td style="width: 1%; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Net loss</td><td> </td> <td style="text-align: left">€</td><td id="xdx_983_eifrs-full--ProfitLossFromOperatingActivities_c20230101__20231231__srt--RestatementAxis__srt--ScenarioPreviouslyReportedMember_zmq0CZ14jeaj" style="text-align: right" title="Operating loss">(5,308,332</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left">€</td><td id="xdx_983_eifrs-full--ProfitLossFromOperatingActivities_c20230101__20231231__srt--RestatementAxis__srt--RestatementAdjustmentMember_znyxtqdv26jk" style="text-align: right" title="Operating loss">(254,025</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left">€</td><td id="xdx_987_eifrs-full--ProfitLossFromOperatingActivities_c20230101__20231231_zOxTpp0NWMEg" style="text-align: right" title="Operating loss">(5,562,357</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Net loss per common share: Basic and diluted</td> <td> </td> <td>€</td> <td style="text-align: right">(0.35</td> <td>) </td> <td> </td> <td>€</td> <td style="text-align: right">(0.01</td> <td>) </td> <td> </td> <td>€</td> <td style="text-align: right">(0.36</td> <td>)</td></tr> </table> At 31 December 2024 <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">As previously reported</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Adjustment</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Restated</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 49%; text-align: left">Amortization expense</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">€</td><td id="xdx_988_eifrs-full--Amortisation_d0_c20240101__20241231__srt--RestatementAxis__srt--ScenarioPreviouslyReportedMember_zS5DTbwmnrMl" style="width: 13%; text-align: right" title="Amortization">–</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">€</td><td id="xdx_980_eifrs-full--Amortisation_iN_di_c20240101__20241231__srt--RestatementAxis__srt--RestatementAdjustmentMember_zYojpeuiLeBh" style="width: 13%; text-align: right" title="Amortization">(304,830</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">€</td><td id="xdx_98F_eifrs-full--Amortisation_iN_di_c20240101__20241231_zDDsUVTJkx4h" style="width: 13%; text-align: right" title="Amortization">(304,830</td><td style="width: 1%; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left"> Net loss</td><td> </td> <td style="text-align: left">€</td><td id="xdx_98A_eifrs-full--ProfitLossFromOperatingActivities_c20240101__20241231__srt--RestatementAxis__srt--ScenarioPreviouslyReportedMember_z55uaBrV9BNa" style="text-align: right" title="Operating loss">(1,320,353</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left">€</td><td id="xdx_982_eifrs-full--ProfitLossFromOperatingActivities_c20240101__20241231__srt--RestatementAxis__srt--RestatementAdjustmentMember_zNyaDQAwfKdj" style="text-align: right" title="Operating loss">(304,830</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left">€</td><td id="xdx_980_eifrs-full--ProfitLossFromOperatingActivities_c20240101__20241231_zt9MkCQHtn8k" style="text-align: right" title="Operating loss">(1,625,183</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Net loss per common share: Basic and diluted</td> <td> </td> <td>€</td> <td style="text-align: right">(0.06)</td> <td> </td> <td> </td> <td>€</td> <td style="text-align: right">(0.01</td> <td>) </td> <td> </td> <td>€</td> <td style="text-align: right">(0.07</td> <td>)</td></tr> </table> At 31 December 2025 <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">As previously reported</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Adjustment</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Restated</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 49%; text-align: left">Amortization expense</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">€</td><td id="xdx_981_eifrs-full--Amortisation_d0_c20250101__20251231__srt--RestatementAxis__srt--ScenarioPreviouslyReportedMember_zzORCmQSttJd" style="width: 13%; text-align: right" title="Amortization">–</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">€</td><td id="xdx_989_eifrs-full--Amortisation_iN_di0_c20250101__20251231__srt--RestatementAxis__srt--RestatementAdjustmentMember_z50yqjQCBAO5" style="width: 13%; text-align: right" title="Amortization">(304,830</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">€</td><td id="xdx_98F_eifrs-full--Amortisation_iN_di_c20250101__20251231_zi8vXMziGKz8" style="width: 13%; text-align: right" title="Amortization">(304,830</td><td style="width: 1%; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Net loss</td><td> </td> <td style="text-align: left">€</td><td id="xdx_989_eifrs-full--ProfitLossFromOperatingActivities_c20250101__20251231__srt--RestatementAxis__srt--ScenarioPreviouslyReportedMember_zdqwMIQq4LC5" style="text-align: right" title="Operating loss">(823,977</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left">€</td><td id="xdx_98F_eifrs-full--ProfitLossFromOperatingActivities_c20250101__20251231__srt--RestatementAxis__srt--RestatementAdjustmentMember_zLqQ2CGSsycg" style="text-align: right" title="Operating loss">(304,830</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left">€</td><td id="xdx_984_eifrs-full--ProfitLossFromOperatingActivities_c20250101__20251231_zi7hegW4ior3" style="text-align: right" title="Operating loss">(1,128,807</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Net loss per common share: Basic and diluted</td> <td> </td> <td>€</td> <td style="text-align: right">(0.03)</td> <td> </td> <td> </td> <td style="width: 1%">€</td> <td style="width: 13%; text-align: right">(0.02</td> <td>) </td> <td> </td> <td>€</td> <td style="text-align: right">(0.05</td> <td>)</td></tr> </table>

254025

-5308332

-254025

-5562357

304830

-1320353

-304830

-1625183

304830

-823977

-304830

-1128807